intestinal flora transplantation compositions and methods for making and using them and devices for

专利摘要:
in alternative embodiments, the invention provides compositions, for example, formulations used for gastric, gastrointestinal and / or colon or lavage treatments, for example, orthostatic lavage, for example, to induce purging (for example, cleaning) of the gastrointestinal tract ( gi), including the colon; and methods for making and using them. in alternative embodiments, the compositions and methods of the invention are used for stabilization, amelioration, treatment and / or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by the side effect of some drug, a physiological condition, a disease or condition such as crohn's disease, a poison, a toxin or an infection, for example, toxin-mediated traveler's diarrhea, or c. difficile or the pseudomembranous colitis associated with this infection. in alternative embodiments, the invention provides drugs and products (articles) of manufacture to transfer these compositions and formulations to an individual, for example, a human or an animal. the invention also provides devices for transferring fecal material to a patient.
公开号:BR112013002667B1
申请号:R112013002667
申请日:2011-08-04
公开日:2020-02-04
发明作者:Thomas Julius Borody
申请人:Thomas Julius Borody；
IPC主号:

专利说明:

“COMPOSITIONS FOR INTESTINAL FLORA TRANSPLANTATION AND METHODS FOR MAKING THEM AND USING THEM AND DEVICES FOR ADMINISTERING THEM”
TECHNICAL FIELD
This invention relates to medicine and gastroenterology, pharmacology and microbiology. In alternative embodiments, the invention provides compositions, for example, formulations or preparations, and devices, used for transplanting a treated or isolated intestinal flora, and methods for making and using them. In alternative embodiments, compositions, devices and methods of the invention can be used for any gastric, gastrointestinal and / or colon treatment or lavage. In alternative embodiments, compositions, devices and methods of the invention are used for the improvement, stabilization and treatment and / or prevention of a disease or condition such as constipation, Crohn's disease, exposure to a poison or toxin or infection, for example, toxin-mediated traveler's diarrhea; or any intestinal disease or condition having a component of intestinal dysfunction, for example, an inflammatory bowel disease (IBD), Crohn's disease, hepatic encephalopathy, entente, colitis, irritable bowel syndrome (IBS), fibromyalgia (FM), chronic fatigue (CFS), depression, attention deficit / hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), traveler's diarrhea, bacterial overgrowth in the small intestine, chronic pancreatitis, or pancreatic insufficiency. In alternative embodiments, the invention provides drugs and products (articles) of manufacture to administer these compositions and formulations to an individual, for example, a human or an animal. The invention also provides devices for delivering fecal material to an individual, for example, a patient.
HISTORIC
The bacterial flora of the intestine has recently gained importance from a therapeutic point of view. It is now realized that human flora, instead of being just residual material from food digestion, is an important virtual organ containing large numbers of living microorganisms. There is an excess of a hundred thousand different subspecies - or more - arranged in families and subgroups of genetically different, but often linearly related, organisms. The residual material forms a part of the flora. The bacterial content of the flora is actively breaking down or metabolizing the unabsorbed material, largely fibers, in which the bacterial cells grow. Because the bacterial flora is contained within the human body and is made up of living components, it is, in fact, a living organ or a virtual organ.
This virtual organ can be healthy in that it does not contain any pathogenic organisms, or it can become infected or infested with parasites, bacteria or viruses. When infected with some pathogenic species, such infectious species can manufacture molecules that affect the secretion, which can cause pain, or can paralyze the intestine causing constipation. Infection of the intestinal flora or organ of the intestinal flora can impact the health of the individual.
Many of these infections can be acute, such as cholera, but some can be chronic and can really impact an individual's life by carrying the infected flora. For example, after antibiotic therapy some of the bacteria's families can be suppressed or eradicated and infectious agents such as Clostridium difficile and other pathogens can lodge and become passengers within the human flora. These 'passengers' are also pathogenic because they can produce toxins, for example, toxins A and B for C. difficile.
DEFINITIONS
The following are some definitions that may be useful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to these terms only, but are placed for a better understanding of the description below.
Unless the context otherwise requires or specifically states otherwise, the numbers, steps or elements of the invention cited here as numbers, steps or singular elements clearly encompass both the singular and plural forms of the numbers, steps or elements cited.
Throughout this specification, unless the context otherwise requires, the word understand, or variations such as understand or understand, will be understood to imply the inclusion of an established step or element or number or group of steps or elements or numbers, but not the exclusion of any other step or element or number or group of elements or numbers. Thus, in the context of this specification, the term comprising means mainly, but not necessarily only.
SUMMARY
According to a first aspect of the present invention, a transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device is provided, comprising: all (or substantially all) a microbiota; a treated or untreated intestinal flora; a complete or partial intestinal flora, an intestinal flora substantially or completely purified from the material of the non-fecal intestinal flora, or an intestinal flora partially, substantially or completely isolated or purified, made through a process comprising:
(i) providing all (or substantially all) a microbiota, a sample of treated or untreated intestinal flora, a sample of complete or partial intestinal flora, a substantially or completely purified intestinal flora of non-fecal intestinal flora material or an intestinal flora partially, substantially or completely isolated or purified; and, a transfer vehicle, formulation, pharmaceutical preparation, composition, manufacturing product, container or device, and (ii) placement of the whole (or substantially all) of the microbiota, the sample of the treated or untreated intestinal flora, the sample of the complete or partial intestinal flora, the intestinal flora substantially or completely purified from non-fecal intestinal flora material, or the intestinal flora partially, substantially or completely isolated or purified in the transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device.
According to a second aspect of the present invention, a manufacturing product (article) is provided comprising a transfer vehicle, formulation, composition, pharmaceutical preparation, container or device of the first aspect.
According to a third aspect of the present invention, a method is provided for making a transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device according to the first or second aspect comprising (i) providing all ( or substantially all) a microbiota; a treated or untreated faecal sample; a sample of the treated or untreated intestinal flora, an intestinal flora substantially or completely purified of material from the non-fecal intestinal flora or an intestinal flora partially, substantially or completely isolated or purified; and, a transfer vehicle, formulation, pharmaceutical preparation, composition, manufacturing product, container or device, and (ii) placing all (or substantially all) of the microbiota, treated or untreated fecal sample, complete or partial intestinal flora, the intestinal flora substantially or completely purified from material of the non-fecal intestinal flora 20 or the intestinal flora partially, substantially or completely isolated or purified in the transfer vehicle, formulation, pharmaceutical preparation, composition, manufacturing product, container or device, and creating a substantially or completely oxygen-free environment in the container or device.
According to a fourth aspect of the present invention, a method is provided for the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning or a condition having a component of bowel dysfunction or side effect, or for improvement, treatment and / or prevention of a constipation, for the treatment of an abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: a drug side effect or a psychological condition or Crohn's disease, a poison , a toxin or infection, toxin-mediated traveler's diarrhea, or an infection with Clostridium or C. perfringens welchii or Clostridium, comprising:
administer to an individual in need of it through a transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device of the first aspect, or a manufacturing product (article) of the second aspect, all (or substantially all) the microbiota, the sample of the treated or untreated intestinal flora, the sample of the complete or partial intestinal flora, the intestinal flora substantially or completely purified from the material of the non-fecal intestinal flora, or the intestinal flora partially, substantially or completely isolated or purified.
According to a fifth aspect of the present invention, a transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device is provided comprising:
whole (or substantially all) a microbiota; an intestinal flora partially, substantially or completely isolated or purified; or a composition comprising an intestinal flora substantially or completely purified from the material of the non-fecal intestinal flora.
According to a sixth aspect of the present invention, a method is provided for the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning or a condition having an intestinal dysfunction component or side effect comprising administering to a individual in need of it through a transfer vehicle, formulation, composition, pharmaceutical preparation, manufacturing product, container or device according to the fifth aspect of all (or substantially) the microbiota, intestinal flora partially, substantially or completely isolated or purified, or the composition comprising an intestinal flora substantially or completely purified of material from the non-fecal intestinal flora.
According to a seventh aspect of the present invention, a device is provided for administering a fecal material or composition of the first aspect, comprising:
(a) a device as shown in Figure 1B or Figure 2; or (b) a device comprising (i) a pouch or container comprising an outlet opening operatively connected to the proximal end of a flexible tube or equivalent, (ii) an opening or closing valve or equivalent or a screw cap plug. at the distal end of the flexible tube or equivalent, and (iii) a pump, a portable pump, for moving material in the bag or container through the flexible tube or equivalent and outside the distal end or outside the opening or closing valve or equivalent; or (c) the device of (a) or (b), further comprising a fecal material or a composition of the first aspect.
According to an eighth aspect of the present invention, a pouch or container is provided comprising: all (or substantially all) a microbiota; a treated or untreated intestinal flora; a complete or partial intestinal flora, a substantially or completely purified intestinal flora of non-fecal material, or a partially, substantially or completely isolated or purified intestinal flora, or a composition of which the pouch or container is structurally the same or similar to a bag or container of a device of the seventh aspect.
According to a ninth aspect of the present invention, a method is provided for the improvement, stabilization, treatment and / or prevention of, or decrease or delay in, symptoms of, an infection, disease, treatment, poisoning or a condition having a component of intestinal dysfunction or side effect, or for the improvement, treatment and / or prevention of constipation, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by:
a side effect of a drug or a psychological condition or Crohn's disease, a poison, a toxin or an infection, a toxin-mediated traveler's diarrhea, or an infection with Clostridium, C. perfringens welchii or C. Difficile or pseudomembranous colitis associated with a Clostridium infection, or to prevent, or decrease or delay the symptoms of, or improve or treat individuals with spondyloarthropathy, spondyloarthritis or sacroiliitis (an inflammation of one or both sacroiliac joints); a nephritis syndrome; an inflammatory or autoimmune condition having a visceral or intestinal component; lupus; irritable bowel syndrome (IBS or spastic colon), or a colitis, Ulcerative Colitis or Crohn's Colitis, constipation, autism, a degenerative neurological disease, amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS) or Parkinson's disease (PD) , a myoclonus dystonia; Steinert's disease; proximal myotonic myopathy; autoimmune disease; Rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA); Chronic Fatigue Syndrome; benign myalgic encephalomyelitis; immune dysfunction syndrome, chronic fatigue; chronic infectious mononucleosis; epidemic myalgic encephalomyelitis; obesity; hypoglycemia; pre-diabetic syndrome, type I diabetes or type II diabetes; idiopathic thrombocytopenic purpura (ITP); acute or chronic allergic reaction; skin rash, diaper rash, hives or chronic hives; and / or insomnia or chronic insomnia, major epileptic seizures or minor epileptic seizures, comprising:
administer to an individual in need of it through a transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of the first aspect or a product (article) manufacturing the second aspect of the whole (or substantially all) of the microbiota, the sample of the treated or untreated intestinal flora, the sample of the complete or partial intestinal flora, the intestinal flora substantially or completely purified of material from the non-fecal intestinal flora, or the intestinal flora substantially or completely isolated or purified, or the intestinal flora partially , substantially or completely isolated in single, repeated or multiple administrations, applications or infusions.
According to a tenth aspect of the present invention, all (or substantially all) of a microbiota is provided, a sample of treated or untreated intestinal flora, a sample of complete or partial intestinal flora, a substantially or completely purified intestinal flora of the material of the non-fecal intestinal flora, or partially, substantially or completely isolated or purified intestinal flora for use in improving, stabilizing, treating and / or preventing an infection, disease, treatment, poisoning or a condition having a component of intestinal dysfunction or side effect , or for the improvement, treatment and / or prevention of a cold, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: a side effect of a drug or a psychological condition or disease Crohn's disease, poison, toxin or infection, toxin-mediated traveler's diarrhea, or an infection with Clostridium or C. perfringens welchii or C. Difficile or a pseudomembranous colitis associated with an infection with Clostridium.
According to an eleventh aspect of the present invention, use is made of all (or substantially all) microbiota, a sample of treated or untreated intestinal flora, a sample of complete or partial intestinal flora, a substantially or completely purified intestinal flora of non-fecal material from the intestinal flora, or intestinal flora partially, substantially or completely isolated or purified in the preparation of a medicine for the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning or a condition having a component of intestinal dysfunction or side effect, or for the improvement, treatment and / or prevention of a cold, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: a side effect of a drug or a psychological condition or Crohn's disease, a poison, a toxin or an infection, a diarrhea that of the traveler mediated by toxin, or an infection by Clostridium or C. perfringens welchii or C. difficile or a pseudomembranous colitis associated with infection by Clostridium.
According to a twelfth aspect of the present invention, use of a seventh aspect device is provided to deliver a fecal material or all (or substantially all) of the microbiota, a sample of the treated or untreated intestinal flora, a sample of the intestinal flora complete or partial, an intestinal flora substantially or completely purified from the non-fecal material of the intestinal flora, or the intestinal flora partially, substantially or completely isolated or purified in the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning or a condition having an intestinal dysfunction component or side effect, or for the improvement, treatment and / or prevention of a cold, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: a side effect of a drug or a psychological condition or Crohn's disease, a poison, a whole xin or an infection, toxin-mediated traveler's diarrhea, or an infection with Clostridium or C. perfringens welchii or C. difficile or a pseudomembranous colitis associated with a Clostridium infection.
In alternative embodiments, the invention provides compositions (including formulations, pharmaceutical compositions, food, feed, supplements, manufacturing products, and the like) comprising: transfer vehicle, formulation, container or device, comprising a treated or untreated intestinal flora, or an intestinal flora partially, substantially or completely isolated; and methods of making and using them.
In alternative embodiments, the invention provides transfer vehicles, formulations, pharmaceutical preparation, manufacturing products, containers or devices, comprising: a treated or untreated intestinal flora, all (or substantially all) the microbiota, and / or a partially intestinal flora , substantially or completely isolated, made through a process comprising:
(a) (i) providing a treated or untreated fecal sample, or a sample comprising all (or substantially all) microbiota, or a composition comprising a complete or partial intestinal flora, or a partially, substantially or completely isolated or purified intestinal flora ; and, a transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device, and (ii) placing the treated or untreated fecal sample, the intestinal flora partially, substantially or completely isolated or purified, all (or. substantially whole) microbiota, or a composition comprising a complete or partial intestinal flora or partially, substantially or completely isolated or purified intestinal flora, in the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device, and optionally creating a substantially environment or completely oxygen-free in the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device, and optionally the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is sterile or bacteria-free before the placement of the treated or untreated fecal sample, or the intestinal flora partially, substantially or completely isolated or purified.
(b) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of (a), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is made substantially or completely free oxygen (for example, at least about 90%, 91%, 92%, 93%, 94%, 95, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99 , 7%, 99.8% or 99.9% oxygen-free) by: incorporating into the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device an embedded or clamped oxygen removal mechanism; and / or; the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device comprises or is coated with an oxygen removal material; and / or completely or substantially replace the air in the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device with nitrogen and / or other non-reactive inert gas or gases.
(c) the transfer vehicle, pharmaceutical preparation, manufacturing product, container or device of (a) or (b), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device simulates (creates) a partially, substantially or completely anaerobic environment;
(d) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any of (a) to (c), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is manufactured, labeled or formulated for human or animal use;
(e) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device (d), in which the animal use is for veterinary use;
(f) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any one of (a) to (e), wherein a stabilizing agent or glycerol is added to, or mixed with, fecal sample treated or untreated, all (or substantially all) microbiota, or the intestinal flora partially, substantially or completely isolated, before storage or freezing, spray drying, cryo drying or lyophilization;
(g) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any of (a) to (f), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is initially manufactured or formulated as a liquid, a suspension, a gel, a gel tablet, a semi-solid, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation, or reformulated for final transfer as a liquid, a suspension, a gel, a gel tablet, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation;
(h) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any of (a) to (g), in which the fecal sample is treated in such a way that the intestinal flora is separated from the material of crude particulate matter in the faecal sample through: homogenization, centrifugation and / or filtration of a crude particulate matter or non-floral matter of the faecal material, or through plasmopheresis, celtrifugation centrifugation, column chromatography (eg affinity chromatography) , immunoprecipitation (for example, antibodies attached to a solid surface, such as beads or a plate);
(i) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any of (a) to (h), in which the treated or untreated intestinal flora, all (or substantially all) microbiota, or the intestinal flora partially, substantially or completely isolated or purified, is lyophilized, cryo dried or frozen, or processed into a powder;
(j) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any one of (a) to (i), where the intestinal flora (including for example, all (or substantially all) microbiota) it is initially derived from an individual filtered or tested for a disease or infection, and / or the intestinal flora is initially derived from an individual filtered to have a wild, normal or healthy population of intestinal flora;
(k) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any one of (a) to (j), in which an isolated or purified intestinal flora or all (or substantially all) microbiota is ( comprises) an isolated intestinal flora that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6 %, 99.7%, 99.8% or 99.9% isolated or pure, or having no more than about 0.1%, 0.2%, 0.3%, 0.4%, 0.5 %, 0.6%, 0.7%, 0.8% 0.9% or 1.0% or more of non-fecal floral material; or (l) the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of any one of (a) to (j), in which the quantity of the treated or untreated fecal sample, all (or substantially all ) microbiota, or partially, substantially or completely isolated or purified intestinal flora is formulated for or calibrated for multiple or repeated transfers or infusions, where optionally the repeated or multiple administration, transfer, infusion or implantation protocol comprises infusions made daily by about from the first 10 days, second daily for about 10 days, third daily then fourth daily possibly weekly and then optionally maintain second or more infusions weekly until histology reverts to normal.
In alternative embodiments, the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of the invention further comprises:
a saline solution, a medium, an anti-foam agent, a surfactant, a lubricant, a neutralizing acid, a marker, a cell marker, a drug, an antibiotic, a contrast agent, a dispersing agent, a buffer or buffering agent, softening agent, de-marking agent, flavoring agent, pH stabilizer, acidifying agent, preservative, purifying agent and / or coloring agent;
at least one vitamin, mineral and / or food supplement, where the vitamin optionally comprises a thiamine, riboflavin, nicotinic acid, pantothenic acid, pyroxidine, biotin, folic acid, vitamin B12, lipoic acid, ascorbic acid, vitamin A, vitamin D , vitamin E, vitamin K, a choline, a camitin, and / or an alpha, beta and / or gamma carotene; or a probiotic nutrient, where the probiotic optionally comprises any ingredient that stimulates the stability, growth and / or activity of the intestinal flora or fecal battery, or optionally comprises, fruit oligosaccharides (FOSs), oligofructose, inulins, galacto oligosaccharides (GOSs), xyl oligosaccharides (XOSs), poly dextrose, monosaccharides, tagatose, and / or mono oligosaccharides.
In alternative embodiments, the invention provides products (articles) of manufacture comprising a transfer vehicle, formulation, pharmaceutical preparation, container or device of the invention.
In alternative embodiments, the invention provides methods for making a transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device, comprising a treated or untreated intestinal flora, all (or substantially all) microbiota, or partially intestinal flora , substantially or completely isolated or purified, comprising:
(a) (i) providing a treated or untreated fecal sample, or a composition comprising a complete or partial fecal flora, all (or substantially all) microbiota, or a partially, substantially or completely isolated or purified intestinal flora; and, a transfer vehicle, pharmaceutical preparation, manufacturing product, container or device, and (ii) placing the treated or untreated fecal sample, the intestinal flora partially, substantially or completely isolated or purified, all (or substantially all) microbiota , or a composition comprising a complete or partial intestinal flora or partially, substantially or completely isolated or purified intestinal flora in the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device, and creating an environment substantially or completely free of oxygen in the container or device;
(b) the method of (a), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is made substantially or completely oxygen-free by: incorporation into the transfer vehicle, formulation, container or device a built-in or clamped oxygen removal mechanism; and / or the transfer vehicle, formulation, pharmaceutical composition, manufacturing product, container or device comprises or is coated with an oxygen withdrawal material; and / or completely or substantially replace the air in the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device with nitrogen and / or other non-reactive inert gas or gases;
(c) the method of (a) or (b), wherein the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device simulates (creates) a partially, substantially or completely anaerobic environment;
(d) the method of any one of (a) to (c), in which the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is manufactured, labeled or formulated for human or animal use;
(e) the method of (d), in which the animal use is for veterinary use;
(f) the method of any of (a) to (e), wherein a probiotic, stabilizing agent or glycerol is added to, or mixed with, treated or untreated fecal sample, or intestinal flora partially, substantially or completely isolated or purified, before storage or cryo drying, spray drying, freezing or lyophilization;
(g) the method of any of (a) to (f), in which the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device is initially manufactured or formulated as a liquid, a suspension, a gel , a gel tablet, a semi-solid, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation, or reformulated for final administration as a liquid, a suspension, a gel, a gel tablet, a semi-solid, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation;
(h) the method of any of (a) to (g), in which the faecal sample is treated in such a way that the intestinal flora is separated from the crude particulate matter in the faecal sample through: homogenization, centrifugation and / or filtration of a raw particulate matter or non-floral matter from the fecal material, or through plasmopheresis, centrifugation, celtrifugation, column chromatography (for example, affinity chromatography), immunoprecipitation (for example, antibodies attached to a solid surface, such as spheres or a plate);
(i) the method according to any one of (a) to (h), wherein the treated or untreated intestinal flora, or partially, substantially or completely isolated or purified intestinal flora, is lyophilized, cryo dried or frozen, or processed into a powder;
(j) the method of any one of (a) to (i), in which the intestinal flora is initially derived from a filtered individual or tested for a disease or infection, and / or the intestinal flora is initially derived from a filtered individual to have a population of the normal, healthy or wild type of intestinal flora; or (k) the method according to any one of (a) to (j), further comprising adding the treated or untreated intestinal flora, or adding to a liquid or solution used to isolate or purify, store, freeze, create, dry , spray drying, lyophilize, transport, reconstitute and / or transfer a treated or untreated intestinal flora (optionally all (or substantially all) microbiota, a partially, substantially or completely isolated or purified intestinal flora, or a composition comprising an intestinal flora substantially or completely purified from non-fecal material of the intestinal flora of the invention):
a saline solution, a medium, an anti-foam agent, a surfactant, a lubricant, a neutralizing acid, a marker, a cellular marker, a drug, an antibiotic, a contrast agent, a dispersing agent, a buffer an agent buffering agent, a smoothing agent, a de-marking agent, a flavoring agent, a pH stabilizer, an acidifying acid, a preservative, a purifying agent and / or coloring agent, and / or at least one vitamin, mineral and / or food supplement, where the vitamin optionally comprises a thiamine, riboflavin, nicotinic acid, pantothenic acid, pyroxidine, biotin, folic acid, vitamin B12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E, vitamin K, a choline, a carnitine, and / or an alpha, beta and / or gamma carotene, and / or a probiotic nutrient, where the probiotic optionally comprises any ingredient that stimulates the stability, growth and / or activity of the entire flora stinal or floral bacteria, or optionally comprises polyols, fruit oligosaccharides (FOSs), oligofructose, inulins, galacto oligosaccharides (GOSs, xyl oligosaccharides (XOSs), poly dextrose, monosaccharides, tagatose, and / or mano oligosaccharides;
(l) the method of any one of (a) to (k), wherein all (or substantially all) microbiota, a substantially isolated or purified intestinal flora is (comprises) an isolate of the intestinal flora that is at least about 90 %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99 , 9% isolated or pure, or having no more than about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0 , 8%, 0.9% or 1.0% or more of non-fecal floral material; or (m) the method of any one of (a) to (I), wherein the amount of all (or substantially all) microbiota, the treated or untreated fecal sample, or the intestinal flora partially, substantially or completely isolated or purified is formulated for or calibrated for transfer or repeated or multiple infusions, where optionally the administration, application, multiple or repeated infusion or implantation protocol comprises infusions made daily for about the first 10 days, second daily for about 10 days, third daily then fourth daily possibly weekly and then optionally maintains second or more infusions weekly until the histology reverts to normal.
In alternative embodiments, the invention provides methods for the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning or a condition having a component of intestinal dysfunction or side effect, or for the improvement, stabilization, treatment and / or prevention of constipation, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: side effect of a drug or a psychological condition or Crohn's disease, a poison, a toxin or a infection, toxin-mediated traveler's diarrhea, or an infection caused by Clostridium or C. difficile or a pseudomembranous colitis associated with a Clostridium infection, comprising administering to an individual in need of it a transfer vehicle, pharmaceutical preparation, manufacturing product , container or device of the invention, or a product (article) manufactured by the invention.
In alternative embodiments, the invention provides methods for the improvement, stabilization, treatment and / or prevention of an infection, disease, treatment, poisoning, or a condition having an intestinal dysfunction component or side effect comprising administering to an individual in need thereof transfer vehicle, formulation, pharmaceutical preparation, product of manufacture, container or device of the invention, or a product (article) of manufacture of the invention, or its contents (for example, bacterial flora contained therein).
In alternative embodiments, the amount of treated or untreated fecal sample, or the intestinal flora partially, substantially or completely isolated or purified is formulated for or calibrated for repeated or multiple transfer or infusions; or the intestinal flora partially, substantially or completely isolated or purified is transferred in repeated or multiple infusions, where optionally the administration, transfer, repeated or multiple infusions or implantation protocol comprises infusions made daily for about the first 10 days, second daily by about 10 days, third daily then fourth daily possibly weekly and then optionally maintain second or more infusions weekly until histology reverts to normal.
In alternative embodiments, methods of infection, disease, treatment, poisoning or condition having a component of intestinal dysfunction or side effect comprise an inflammatory bowel disease (IBD), Crohn's disease, hepatic encephalopathy, entente, colitis, Irritable bowel syndrome ( IBS), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit / hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), traveller's diarrhea, bacterial overgrowth of the small intestine, chronic pancreatitis, pancreatic insufficiency, exposure to a poison or toxin or infection, toxin-mediated traveler's diarrhea, poisoning, pseudomembranous colitis, infection by Clostridium, C. perfringens welchii or Clostridium difficile, neurological condition, mal de Parkinson's, myoclonus dystonia, autism, amyotrophic lateral sclerosis, multiple sclerosis, large s epileptic seizures and minor epileptic seizures. In alternative embodiments, the amount of treated or untreated fecal sample, or the intestinal flora partially, substantially or completely isolated or purified, is formulated for or calibrated for repeated or multiple transfer or infusions; either the treated or untreated faecal sample or the intestinal flora partially, substantially or completely isolated or purified is administered in repeated or multiple infusions, where optionally the multiple or repeated administration, transfer, infusion, or implantation protocol comprises infusions made daily by about the first 10 days, second daily for about 10 days, third daily then fourth daily or possibly weekly and then optionally maintaining second or more infusions weekly until the histology reverts to normal.
In alternative embodiments, the invention provides transfer vehicles, formulations, pharmaceutical preparations, manufacturing products, containers or devices comprising:
(a) all (or substantially all) microbiota, a partially, substantially or completely isolated or purified intestinal flora, or a composition comprising a substantially or completely purified intestinal flora of non-fecal material from the intestinal flora, and optionally further comprising an excipient, or a fluid, a saline solution, a buffer, a buffering agent or a medium, or an agarfluid-glucose-cellobiose (RGCA) medium;
(b) the composition, container or device, formulation, or manufacturing product of (a), wherein all (or substantially all) microbiota or intestinal flora is isolated or purified from human or animal fecal material;
(c) the composition, container or device, formulation, or manufacturing product of (a) or (b), wherein all (or substantially all) microbiota or intestinal flora is isolated or purified using a method or protocol comprising use of a centrifuge, a celtrifuge, an immunoaffinity column or column, or in which all (or substantially all) microbiota or intestinal flora is isolated or purified through a method comprising homogenizing, centrifuging and / or filtering a raw particulate matter or a non-floral matter from the fecal matter, or through plasmopheresis, centrifugation, celtrifugation, column chromatography (for example, affinity chromatography), immunoprecipitation (for example, antibodies attached to a solid surface, such as beads or a plate);
(d) the composition, container or device, formulation, or manufacturing product of any of (a) to (c), wherein all (or substantially all) microbiota or the substantially or completely isolated or purified intestinal flora or flora intestinal substantially or completely purified from non-fecal material of the intestinal flora, is in a substantially or completely oxygen-free environment in the composition, container or device, formulation, or manufacturing product;
(e) the transfer vehicle, formulation, container or device of (d), wherein the composition, container or device, formulation, or manufacturing product is made substantially or completely oxygen-free through: incorporation into the transfer vehicle, formulation, container or device a built-in or clamped oxygen removal mechanism; and / or, the transfer vehicle, formulation, container or device comprises or is coated with an oxygen removal material; and / or completely or substantially replace the air in the transfer vehicle, formulation, container or device with nitrogen and / or other non-reactive inert gas or gases;
(f) the composition, container or device, formulation, or manufacturing product of any of (a) to (c), wherein all (or substantially all) microbiota, the substantially or completely isolated or purified intestinal flora, or intestinal flora substantially or completely purified from non-fecal material of the intestinal flora, is in a substantially or completely anaerobic environment;
(g) the composition, container or device, formulation, or manufacturing product of any of (a) to (f), wherein the transfer vehicle, formulation, container or device is manufactured, labeled or formulated for animal use or human;
(h) the composition, container or device, formulation, or manufacturing product of (g), in which the animal use is for veterinary use;
(i) the composition, container or device, formulation, or manufacturing product of any of (a) to (h), wherein a stabilizing agent or glycerol is added to, or mixed with, all (or substantially all) microbiota, or the intestinal flora partially, substantially or completely isolated or purified, or the composition comprising an intestinal flora substantially or completely purified from non-fecal material of the intestinal flora, prior to storage or freezing, freeze drying, spray drying or lyophilization;
0) the composition, container or device, formulation, or manufacturing product of any of (a) to (f), wherein the composition, container or device, formulation, or manufacturing product is initially manufactured or formulated as a liquid , a suspension, a gel, a gel tablet, a semi-solid, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation, or reformulated for final transfer as a liquid, a suspension, a gel, a tablet gel, a semi-solid, a tablet, a sachet, a lozenge or a capsule, or as an enteral formulation;
(k) the composition, container or device, formulation, or manufacturing product of any of (a) to (j), wherein all (or substantially all) microbiota, or the intestinal flora partially, substantially or completely isolated or purified , or the composition comprising an intestinal flora substantially or completely purified from non-fecal material of the intestinal flora, is lyophilized, dried, powdered, or frozen;
(l) the composition, container or device, formulation, or manufacturing product of any of (a) to (k), in which all (or substantially all) microbiota or intestinal flora is initially derived from a filtered or tested individual for a disease or infection, and / or all (or substantially all) microbiota or intestinal flora is initially derived from an individual filtered to have a population of the normal, healthy or wild type of intestinal flora; or (m) the composition, container or device, formulation, or manufacturing product of any one of (a) to (I), further comprising adding to all (or substantially all) microbiota, the intestinal flora partially, substantially or completely isolated or purified, or a composition comprising a gut flora substantially or completely purified of non-fecal material from the gut flora, or add to a liquid or solution used to isolate or purify, store, freeze, cry dry, spray dry, lyophilize, transport, reconstitute and / or administer treated or untreated intestinal flora:
a saline solution, a medium, a defoamer, a surfactant, a lubricant, a neutralizing acid, a marker, a cell marker, a drug, an antibiotic, a contrast agent, a dispersing agent, a buffer or buffering agent, a smoothing agent, a de-marking agent, a flavoring agent, a pH stabilizer, an acidifying agent, a preservative, a purifying agent and / or coloring agent, and / or at least one vitamin, mineral and / or food supplement, where the vitamin optionally comprises a thiamine, riboflavin, nicotinic acid, pantathenic acid, pyridoxine, folic acid, vitamin B12, lipoic acid, ascorbic acid, vitamin A, vitamin D, vitamin E, vitamin K, a choline, a carnitine, and / or an alpha, beta and / or gamma carotene, and / or a probiotic nutrient, where the probiotic optionally comprises any ingredient that stimulates the stability, growth and / or activity of all (or su substantially all) microbiota or intestinal flora or fecal bacteria, or optionally comprises, polyols, fruit, oligosaccharides (FOSs), oligofructose, inulins, galacto oligosaccharides (GOSs), xyl oligosaccharides (XOSs), poly dextroses, monosaccharides, tagatoses, and tagatoses, and tagatoses oligosaccharides mano;
(n) the composition, container or device, formulation, or manufacturing product of any of (a) to (m), wherein a substantially isolated or purified intestinal flora is (comprises) an isolate from all (or substantially all) microbiota or intestinal flora that is at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% isolated or pure, or having no more than about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1.0% or more of the material of the intestinal flora; or (m) the composition, container or device, formulation, or manufacturing product of any of (a) or (I), wherein the amount of all (or substantially all) microbiota or the treated or untreated fecal sample, or partially, substantially or completely isolated or purified intestinal flora is formulated for or calibrated for repeated or multiple transfer or infusions, where optionally the repeated or multiple administration, application, infusion or implantation protocol comprises infusions made daily for about the first 10 days, second daily about 10 days, third daily then fourth daily possibly weekly and then optionally to keep second or more infusions weekly until the histology reverts to normal.
In alternative embodiments, the invention provides methods for ameliorating, stabilizing, treating and / or preventing an infection, treatment, poisoning or a condition having an intestinal dysfunction component or side effect comprising administering to a subject in need a composition, container or device, formulation, or manufacturing product of the invention.
In alternative embodiments, methods of infection, disease, treatment, poisoning or condition having a component of intestinal dysfunction or side effect comprise an inflammatory bowel disease (FDI), Crohn's disease, hepatic encephalopathy, entente, colitis, irritable bowel syndrome ( IES), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit / hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), traveller's diarrhea, bacterial overgrowth of the small intestine, chronic pancreatitis, pancreatic insufficiency, exposure to a poison or toxin or infection, toxin-mediated traveler's diarrhea, poisoning, pseudomembranous colitis, infection by Clostridium, C. perfringens welchii or Clostridium difficile, a neurological condition, Parkinson's disease, myoclonus dystonia, autism, amyotrophic lateral sclerosis, sclero if multiple, major epileptic seizures and small epileptic seizures.
In alternative embodiments, the invention provides methods for improving, stabilizing, treating and / or preventing, or decreasing or delaying the symptoms of, an infection, disease, treatment, poisoning or condition having a component of intestinal dysfunction or side effect, or for the improvement, treatment and / or prevention of a constipation, for the treatment of abdominal pain, non-specific abdominal pain or diarrhea, diarrhea caused by: side effect of a drug or a psychological condition or Crohn's disease, a poison, a toxin or infection, toxin-mediated traveler's diarrhea, or an infection caused by Clostridium or C. perfringens welchii or C. difficile or a pseudomembranous colitis associated with a Clostridium infection, or to prevent, decrease or delay symptoms , improve, stabilize or treat individuals (e.g., patients or animals) with spondyloarthropathy, spondyloarthritis or sacrum ileitis (an inflammation of one or both sacriliac joints); nephritis syndrome; an inflammatory or autoimmune condition having a visceral or intestinal component such as lupus, irritable bowel syndrome (IBS or spastic colon) or a colitis such as Ulcerative Colitis or Crohn's colitis; constipation, autism; degenerative neurological diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) or Parkinson's disease (PD); myoclonus dystonia (for example, Steinert's disease or proximal myotonic myopathy); an autoimmune disease such as Rheumatoid Arthritis (RA) or juvenile idiopathic arthritis (JIA); Chronic Fatigue Syndrome (including benign myalgic encephalomyelitis, chronic fatigue immune dysfunction syndrome, chronic infectious mononucleosis, epidemic myalgic encephalomyelitis); obesity; hypoglycemia, pre-diabetic syndrome, type I diabetes or type II diabetes; idiopathic thrombocytopenic purpura (ITP); a chronic or acute allergic reaction such as skin rash, diaper rash, hives or a chronic hives; and / or insomnia or chronic insomnia, minor epileptic seizures or major epileptic seizures, comprising:
administering to an individual in need thereof a transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device of the invention, or a manufacturing product (article) of the invention, in single, repeated or multiple administrations, transfers or infusions.
In alternative embodiments, the amount of the whole (or substantially all) microbiota, the treated or untreated fecal sample, or the intestinal flora partially, substantially or completely isolated or purified, is formulated for or calibrated for repeated or multiple transfer or infusions; or all (or substantially all) microbiota, the treated or untreated fecal sample or the partially, substantially or completely isolated or purified intestinal flora is transferred in repeated or multiple infusions, where optionally the repeated or multiple administration, transfer / infusion or protocol implantation comprises infusions made daily for about the first 10 days, second daily for about 10 days, third daily then fourth daily possibly weekly infusions and then optionally maintain second or more infusions weekly until histology reverts to normal.
In alternative embodiments, the invention provides devices for delivering a (bacterial flora comprising) composition of the invention, or all (or substantially all) microbiota or fecal material comprising:
(a) a device as shown in Figure 1 or Figure 2, or an equivalent thereof; or (b) (1) a pouch or container comprising an outlet opening operatively connected to the proximal end of a flexible tube or equivalent, wherein the pouch or container is optionally made of a material impervious to gas or oxygen, and optionally the pouch or container is made of a flexible material, or a polyethylene terephthalate polyester film comprising (or a MYLAR ™ comprising) material, and optionally the pouch or container is an intravenous pouch (type IV), and optionally a bag or container has a connection that will allow the bag to be hung on a support, for example, to be positioned / hung over an endoscope, and optionally the bag or container is operationally connected via an opening or closing valve or equivalent to a negative pressure device that can remove all gas or air from the bag, and optionally the bag or container is operationally connected to through an opening or closing valve or equivalent to a fluid source or storage container to discharge the bag through the outlet opening, and optionally the fluid source or storage container is under positive pressure, and optionally the flexible tube or equivalent comprises at least one clip or shut-off valve or a one-way valve to prevent backwashing of material from the distal part to the proximal part of the tube, or from the tube back to the bag or container;
(2) an opening or closing valve or equivalent or a screw cap plug at the distal end of the flexible tube or equivalent, and optionally a locking latch for connection to a colonoscope or an endoscope locking port or equivalent, where optionally the locking latch is embedded in the valve, or is separate from the valve, and optionally an enema tube tip for connection to an enema tube or device or equivalent, where optionally the enema tube tip is embedded in the valve, or is separate from the valve, and optionally further comprises a safety device or safety clip to close the distal opening in the event that the valve or snap lock, or enema tip, is lost (flies) under pressure; and (3) a pump, a portable pump, for moving material in the bag or container through the flexible tube or equivalent and outside the distal end or outside the opening or closing valve or equivalent; or (c) the device of (a) or (b), further comprising a fecal material or a composition of the invention.
In alternative embodiments, the invention provides bags or containers comprising all (or substantially all) microbiota, or treated or untreated intestinal flora, or partially, substantially or completely isolated intestinal flora, or a composition of the invention (for example, a formulation comprising whole (or substantially all) a microbiota, a partially, substantially or completely isolated or purified intestinal flora, or a composition comprising a substantially or completely purified intestinal flora of non-fecal material from the intestinal flora), and optionally further comprising an excipient, or a fluid, a saline solution, a buffer, a buffering agent or a medium, fluid-glucose-cellobiosis agar (RGCA) medium, wherein the pouch or container is structurally the same or similar to a pouch or container of a device of the invention (for example, as illustrated in Figure 1 or Figure 2), in that optionally the interior of the bag is substantially or completely an oxygen-free environment, or the interior of the bag is substantially or completely similar to an anaerobic environment.
In alternative embodiments, specific anto C. difficile oral antibodies (eg, avian) can be added to a solution (eg, saline, medium, buffer) used to isolate or purify, store, freeze, cry dry, spray dry, lyophilize, transport, reconstitute and / or administer a composition (e.g., partially, substantially or completely isolated or purified intestinal flora, or a composition comprising a substantially or completely purified intestinal flora of non-fecal material from the intestinal flora) of the invention. Combining the product with these specific oral C. difficile antibodies increases the product's eradication mechanism.
Details of one or more embodiments of the invention are set out in the accompanying drawings and description below. Other aspects, objectives, and advantages of the invention will be apparent from the description and drawings, and from the claims.
All publications, patents, patent applications cited here are expressly incorporated by reference for all purposes.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings set forth here are illustrative of embodiments of the invention and are not intended to limit the scope of the invention as encompassed by the claims.
Figure 1A illustrates an exemplary storage device of the invention; and, Figure 1B illustrates an exemplary delivery device of the invention, as described below.
Figure 2 illustrates an exemplary delivery device of the invention.
Similar reference symbols in the various drawings indicate similar elements. Reference will now be made to several exemplary embodiments of the invention, examples of which are illustrated in the accompanying drawings. The following detailed description is provided to give the reader a better understanding of certain details of the aspects and embodiments of the invention, and should not be construed as limiting the scope of the invention.
DETAILED DESCRIPTION
In alternative embodiments, the invention provides compositions, for example, pharmaceutical formulations and preparations, manufacturing products, and transfer containers and vehicles, and transfer devices and materials, comprising treated and / or isolated fecal material for transplantation of intestinal flora. In one embodiment, the treated and / or isolated fecal material of the invention comprising the intestinal flora (for example, bacteria) is transplanted between different individuals, for example, human to human or between animals. In one embodiment, the treated fecal material of the invention is transplanted back to the same individual from which it was collected, for example, to repopulate a colon after drug treatment (for example, antibiotic treatment or chemotherapy) or after an orthostatic wash, for example. example, to induce purging (for example, cleaning) of a gastrointestinal (Gl) tract, including a colon.
The invention provides methods for ameliorating, stabilizing, or treating an intestinal disease or infection comprising use of a transfer vehicle, formulation, manufacturing product, or container or device of the invention; for example, as a fecal bacteriotherapy, fecal transfusion, fecal transplant or human probiotic infusion (HPI). In alternative embodiments, the invention provides methods for improving, stabilizing, treating or preventing any infection, intestinal disease or condition having a component of intestinal dysfunction, for example, poisoning, pseudomembranous colitis, infection with Clostridium difficile, inflammatory bowel disease (IBD), Crohn's disease, hepatic encephalopathy, entente, colitis, irritable bowel syndrome (IBS), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit / hyperactivity disorder (ADHD), sclerosis multiple (MS), systemic lupus erythematosus (SLE), traveller's diarrhea, bacterial overgrowth of the small intestine, chronic pancreatitis or pancreatic insufficiency.
For example, in one embodiment, as antibiotics do not eradicate C. difficile and its spores, a transfer vehicle, formulation, manufacturing product, or container or device of the invention comprising treated and / or isolated intestinal flora can improve, stabilize or eradicate C. difficile (or the pseudomembranous colitis associated with this infection) when infused into a colon of the infected or sick individual, for example, a patient or animal. In alternative embodiments, the intestinal flora obtained from a donor (which in the treated or isolated form is in the alternative embodiments in a transfer vehicle, formulation, manufacturing product, or container or device of the invention) comprises part of, substantially all, or all of the missing or inadequate infected or sick recipient (for example, in numbers or function) of the intestinal flora, for example, bacteria. While the invention is not limited by any particular mechanism of action, in some embodiments it is the transfer of the equivalent of: a part of, substantially all, or all of the intestinal flora of the infected individual from the donor to the recipient (for example, from human to that improves or eradicates the infection or the pseudomembranous colitis associated with this infection.
In alternative embodiments, the compositions, for example, pharmaceutical formulations and preparations, and devices, transfer materials, transfer vehicles, manufacturing products, containers and devices of the invention allow for the safe transplantation of components of the intestinal flora (for example, human flora ) for individuals in need of these, for example, for infected, sick and dying patients, thus providing a flora still functioning consistently safe to transfer to a recipient or patient.
In alternative embodiments, the invention provides a reliable method for producing a fresh, standardized intestinal flora that can have a long shelf life. For example, in one embodiment, the transfer vehicle, formulation, pharmaceutical preparation, manufacturing product, container or device comprising the intestinal flora comprises a substantially or completely oxygen-free environment.
In another embodiment, nutrients such as probiotic nutrients can be added (for example, in dry or liquid forms) to a solution (for example, saline, medium, buffer) used to isolate or purify, store, freeze, freeze, dry by spraying, lyophilizing, transporting, reconstituting and / or transferring a composition (e.g., partially, substantially or completely isolated or purified intestinal flora, or a composition comprising a substantially or completely purified intestinal flora of the non-fecal material of intestinal flora) of the invention . A probiotic nutrient can be any ingredient that stimulates the stability, growth and / or activity of the intestinal flora, for example, bacteria; for example, in alternative embodiments, polyols, fruit oligosaccharides (FOSs), oligofructose, inulins, galactooligosaccharides (GOSs), xyl oligosaccharides (XOSs), poly dextrose, monosaccharides such as tagatose, and / or mano oligosaccharides are used as probiotics invention. In one embodiment, probiotics are added to prevent 'shock' to the intestinal flora following isolation or purification, freezing, freeze-drying, spray drying, reconstitution in solution and the like.
In alternative embodiments, components of the compositions, for example, transfer vehicles, pharmaceutical formulations and preparations, manufacturing products, or containers or devices, of the invention comprise all (or substantially all) a microbiota, or a Bacteroides and / or Firmicutes in large numbers (for example, a greater proportion of Bacteroides and / or Firmicutes is present which is normally found in situ), for example, capable of improving and / or eradicating a C. difficile infection and / or pseudomembranous colitis associated with this infection. In alternative embodiments, the compositions, for example, transfer vehicles, pharmaceutical formulations and preparations, manufacturing products, or containers or devices, of the invention may be available (for example, formulated and / or dosed for) for recurrent use in individuals, for example, in patients or animals, with more difficulty treating conditions such as colitis (for example, pseudomembranous colitis from a C. difficile infection) and constipation.
In alternative embodiments, components of the compositions, for example, transfer vehicles, pharmaceutical formulations and preparations, manufacturing products, or containers or devices, of the invention comprise a selection of bacterial species, for example,
Bacteroides, Firmicutes, Bacillus thuringiensis (a bacterium capable of producing antibiotics for C. difficile). Bacterial species can be separated through celltrifugation or plasmopheresis.
In alternative embodiments the selection of bacterial species, for example, Bacteroides, Firmicutes, Bacillus thuringiensis can be added to components of the compositions, for example, transfer vehicles, formulations, and pharmaceutical preparations, manufacturing products, or containers or devices such as fortification of concentrations comprising bacterial species to contain wild types of bacteria.
In alternative embodiments, the compositions of the invention can be formulated as faecal suspensions, saline or buffered suspensions (for example, for an enema, suspended in a tampon or saline), in a drink (for example, milk, yogurt, a shake, a flavored drink or equivalent) for oral administration, and the like.
In alternative embodiments, compositions of the invention can be formulated as an enema product, a spray dried product, reconstituted enema, a small capsule product, a small capsule product suitable for administration to children, a syringe, a syringe suitable for a homemade enema with an addition of saline solution, a powder product, a powder product in oxygen-free sachets, a powder product in oxygen-free sachets that can be added to, for example, a syringe or enema, or a dry product by spraying on a device that can be attached to a container with an appropriate means of transport such as yogurt or milk and that can be directly incorporated and given as a dosage, for example, for children.
In one embodiment, the compositions of the invention can be transferred directly on a transport medium through a screw cap where the fecal material is suspended in the cap and released by turning the cap directly on the transport means.
In alternative embodiments, methods of transferring the compositions of the invention include use of fecal suspensions in the intestine, via an enema suspended in saline or buffer, orally in a beverage (for example, milk, yogurt, flavored beverage and the like), via a small intestinal infusion through a naso-duodenal tube, through a gastrostomy, or using a colonoscope. In some embodiments, there may be advantages to transferring through a colonoscope to infuse as soon as possible, and to detect any pathology of the colon.
In the methods of the alternative embodiments, the intestinal flora used in the composition and methods of the invention is initially derived (entirely or in part) from an individual filtered or tested for a disease or infection, and / or the intestinal flora is initially derived from a filtered individual to have a representative normal, healthy or normal population, of the wild type of intestinal flora; for example, a normal complement to a Bacteroides and / or Firmicutes, and / or another intestinal force such as Bacillus Thuringiensis. In one embodiment, depending on the deficiency of a floral species (for example, bacterial) in a fecal material donor, or to achieve a desired effect, one or more additional (or supplementary) species, for example, Bacteroides, Firmicutes and / or Bacillus Thuringiensis, the transfer product is added (or administered with) either initially when the product is made, or at the time of transfer, for example, additional species are / are mixed before application to the subject (for example, patient or animal), for example, when a powder, lyophilized or dried cryo composition is reconstituted for transfer; or to one or more additional (or supplementary) species may be co-administered. These additional floral species can be directly isolated or purified from a donor, or they can be expanded (grown) for a time in vitro before addition, or they can come from (be derived from) a pure culture, for example, of an ATTC stock.
For example, in some applications, for example, to achieve a desired effect or therapeutic result, a transfer of an increased amount of one or more species of intestinal flora (for example, bacterial) is used, for example, the transferred product (for example, example, all (or substantially all) microbiota, or a composition comprising a complete or partial intestinal flora, or a partially, substantially or completely isolated or purified intestinal flora) is augmented with (is studded with) one or more additional (or supplementary) species ), for example, Bacteroides, Firmicutes and / or Bacillus Thuringiensis, which can be directly isolated from a donor, or can come from a pure culture, and the like.
In some embodiments, donor selection is of crucial importance, for example, to avoid infecting the recipient with a separate infection or disease. In alternative embodiments the donor is tested (filtered) at least for, for example, retrovirus (for example, human immunodeficiency virus, HIV); hepatitis A, B, and / or C; cytomegalovirus; Epstein-Barr virus, detectable parasites and / or bacterial pathogens, depending on the donor and recipient species, for example, human or animal.
In alternative embodiments, the invention provides a process for preparing the intestinal flora (for example, all (or substantially all) microbiota) for transplantation, first comprising a collection of one or more healthy donors (for example, filtrates). In alternative embodiments, fresh feces are transported via a faeces collection device of the invention, which in one embodiment comprises an appropriate container suitably oxygen-free (or substantially oxygen-free). A suitable exemplary stool collection device 1 is shown in Figure 1A. Figure 1A shows an exemplary container of the invention for containing feces and including a compartment 2 for receiving feces. The container can then be placed in a bag 3 suitably in a sealed leak-proof ziplock bag.
In alternative embodiments, the container can be made oxygen-free, for example, by incorporating an embedded or removed oxygen removal mechanism in the container, for example, oxygen removal tablets as described, for example, in US Patent Document No. 7,541,091. In another embodiment, the container itself is made of an oxygen withdrawal material, for example, oxygen-capturing iron, for example, as described by O2BLOCK ™, or equivalent, which uses a purified and modified layered clay as a carrier increasing the performance of oxygen-trapping iron; the active iron is dispersed directly in the polymer. In one embodiment, the oxygen withdrawal polymers 5 are used to form the container itself or to coat the container, or as tablets to be added; for example, as described in U.S. Patent Application Document Pub. 20110045222, describing polymer mixtures having one or more unsaturated olefinic homopolymers or copolymers; one or more polyamide homopolymers or copolymers 10; one or more homopolymers or copolymers of polyethylene terephthalate; that exhibit oxygen withdrawal activity. In one embodiment, the oxygen withdrawal polymers are used to make the container itself or to coat the container, or as tablets to be added; for example, as per U.S. Patent Application 15 Pub. 20110008554, describing compositions comprising a polyester, a copolyester ether and an oxidation catalyst, wherein the copolyester ether comprises a polyester segment comprising poly (tetramethylene-co- alkylene ether). In one embodiment, the oxygen withdrawal polymers are used to make the container itself or to coat the container, or as tablets to be added; for example, as described in U.S. patent application document Pub. 201000255231, describing a dispersed iron / salt particle in a polymer matrix, and an oxygen removal film with oxygen removal particles.
Alternatively, in addition to or in place of the oxygen removal mechanism, the air in the container is replaced (completely or substantially) with nitrogen and / or other inert non-reactive gas or gases. In alternative embodiments, the container simulates (creates) a partially, substantially or completely anaerobic environment.
In alternative embodiments, the faeces (for example, fecal sample) are kept in an aesthetically acceptable container that will not leak or spread a smell while maintaining an anaerobic environment. In alternative embodiments, the container is sterile before receiving fecal flora.
In alternative embodiments, the container is kept below room temperature, for example, refrigerated, during most or all of its preparation, transportation and / or storage, for example, a stool bank or in the place where the transplant will take place. For example, once taken to a stool processing bank, it is stored in a cool environment, cold container or refrigerator to minimize flora metabolism. In alternative embodiments, it should not be frozen to prevent the destruction of bacterial cells in the stool.
In alternative embodiments, stabilizing agents such as glycerol are added to the collected and / or stored material. In one embodiment, the faeces are suddenly frozen in nitrogen or any similar refrigerant, for example, so that they can be stored for extended periods of time while waiting for processing.
In alternative embodiments, feces are tested for various pathogens, as noted above. In alternative embodiments, once the infectious agents have been removed, the faeces are homogenized and filtered to remove large particles of matter. In alternative embodiments, they are subdivided into desired volumes, for example, which can be between 5 cc and 3 or more liters. For example, in one embodiment, a container comprises 50 grams (g) of feces, which can be kept in an appropriate oxygen-resistant plastic, for example, a metallized polyethylene terephthalate polyester film, or metallized MYLAR ™.
In the alternative embodiments, as shown in Figure 1B, the exemplary therapeutic vehicle (transfer system) 10 and the equipment in which the stool material is kept is an intravenous type (type IV) set 11, for example, with a portable pump 12 connected to the set. Suitably bag 11 is metallic MYLAR ™ which is impervious to gases. The portable pump 12 can allow the contents of the liquidized feces residing in the upper part of the plastic device to be easily pumped forward when all the piping equipment is connected through the Luer locking mechanism 13 to the colonoscope's biopsy channel. In this way, a colonoscopy or even an enteroscope will become the transfer mechanism. For this embodiment, it would usually be in the colon at any distance, and alternatively in the cecum.
In alternative embodiments, the material is passed through a terminal ileum or even higher, as desired.
In alternative embodiments, it can be infused in the duodenum or below with an enteroscope. In alternative embodiments, C. difficile (or the pseudomembranous colitis associated with this infection) is improved or eradicated with the infused fecal sample, or treated stools.
Another alternative embodiment is shown in Figure 1. In this embodiment, the therapeutic vehicle / transfer system 20 including a type IV pouch 21 including saline (NaCl) 22 and feces / cells 23 of the invention. In addition to the portable pump 24 and the Luer lock 25, the transfer system 15 is provided with a discharge port 26 (to unload the bag), a clip 27 (to prevent backwashing) and an enema tip 28 with fixation Luer lock.
In alternative embodiments, the transplant material is subjected to homogenization and effort. In alternative embodiments, this treated material is placed in the container, for example, a pouch, which can be attached to a nasogastric or naso-duodenal tube to allow the contents to be infused, for example, or in the stomach, duodenum or in the distal jejunum. Alternatively it can be kept in a container, for example, a pouch, which can be attached to an end of the enema to be given as an enema.
In alternative embodiments, to separate the non-bacterial components and produce a stable product that can be frozen or lyophilized and have a long shelf life, the faeces can be homogenized and filtered through the crude particulate matter. In the 30 alternative embodiments, the microscopic fiber / non-living matter is then separated from the bacteria. Several methods can be used, including, for example, recurrent filtration with filter sizes, for example, coming from the size of the bacteria.
In one embodiment, different filters are used to isolate the bacterial species. This differs from the technique used, for example, by Williams in WO 2011 / 033310A1 which uses a crude filtration technique with a gauze and is less than that of the present invention which uses different dimensions of filtration membranes to obtain the purified bacteria .
In one embodiment, a filtration procedure to filter all feces is suitably used to achieve the highest concentration of almost 100% bacteria. In one embodiment, the filtration procedure is a two-step procedure suitably using deep glass fiber filters for initial clarification. In one embodiment, the faeces are filtered under positive pressure. In one embodiment, this would be using a combination or sandwich configuration with a 30 micron PVDF filter. In one embodiment, this sandwich procedure will be filtering the product under positive pressure. Later, the membrane concentration can, in one embodiment, be used as another step to reduce the volume of the filtrate. In one embodiment, this can be done before drying or spray drying under the nitrogen blanket.
Alternative membranes that can be used for filtration 20 include, but are not limited to, nylon filters, cellulose nitrate filters, PES filters, Teflon filters, mixed ester and cellulose filters, polycarbonate filters, polypropylene filters, PVC filters or quartz filters. Various combinations of these can be used to achieve high bacterial purity with solids and liquids removed promptly to freeze, spray dry or lyophilize.
In order to freeze, in alternative embodiments, the bacteria is kept in a liquid that will prevent the burning of the cells during thawing. This can include various stabilizers, for example, glycerol and suitable buffers, and / or ethylene glycol. In the 30 alternative embodiments, cryo protection uses final concentrations of stabilizer (s) of between about 20% to 60%, depending on the stabilizer (s) used; this helps to stabilize proteins by preventing the formation of ice crystals that would otherwise destroy protein structures.
In alternative embodiments, stabilizers that help reduce the destruction of live bacteria include skim milk, erythritol, arabitol, sorbitol, glucose, fructose and other polyols. Polymers such as dextran and polyethylene glycol can also be used to stabilize fecal bacterial cells.
Mixing the appropriate amount of bacterial flora with the stabilizer allows it to be promptly frozen and kept frozen in the container that will be used to transport it to the appropriate location where the patient will have it infused after thawing.
In alternative embodiments, all (or substantially all) microbiota, or an isolated and / or treated fecal material (e.g., purified or isolated) and / or flora, can be lyophilized or chromium dried, or the product can be frozen. In alternative embodiments, cryo drying allows the majority of cells to remain viable, and to produce a powder form of the product that can be gently sprayed into a powder. The powder, or lyophilized or cryo dried or isolated flora, can then be encapsulated in a carrier, for example, a tablet, a gel tablet, pill or capsule, for example, a coated enteric capsule, or placed in oil capsules for ingestion. Alternatively, the dried or lyophilized cryo product, or powder, can be reconstituted prior to transfer to an individual in, for example, a fluid, for example, a sterile fluid, such as saline, a buffer or a medium such as a fluid-glucose-cellobiosis agar (RGCA).
In alternative embodiments, all (or substantially all) microbiota, or an isolated and / or treated fecal material (for example, purified or isolated) and / or flora can be dried. In one embodiment, spray drying is preferred over cryo drying or lyophilization.
In alternative embodiments, all (or substantially all) microbiota, or flora and / or fecal material isolated and / or treated, is supplemented with wild-type bacteria that may have been derived from the flora of the normal animal (for example, human) and / or treated recombinant bacteria, for example, reoombinating microorganisms that can synthesize a protein, small molecule or carbohydrate that has a self-protecting or improving effect; or recombinant microorganisms that can be self-destructive when provided with an appropriate signal, for example, a chemical delivered by ingestion.
In alternative embodiments, the transplant product (for example, a composition of the invention comprising an isolated or purified intestinal flora or all (or substantially all) microbiota) is transferred by an infusion, for example, through the rectum, mouth or through the tract upper gastrointestinal (Gl), or can be used in a suppository pill, tablet or encapsulated form, for example, with an enteric coated gradual release capsule or a tablet, for example, with the addition of excipients. In alternative embodiments, the transplant product is administered as a suppository to give the highest concentration in the rectum.
In one embodiment, the transplant product (for example, a composition of the invention comprising an isolated or purified intestinal flora or all (or substantially all) microbiota) is stored before, during and / or after transfer to an individual, or for or during transfer, in a fluid, for example, a sterile fluid, such as saline, a buffer or a medium such as fluid-glucose-cellobiose agar (RGCA) medium.
In alternative embodiments, the compositions and methods of the invention are used to improve, stabilize, prevent and / or treat: various gastrointestinal conditions, for example, infection by C. Difficile, C. perfringens welchii and other infections by Clostridium, irritable bowel syndrome , constipation, bolsite, Crohn's disease and microscopic colitis; neurological conditions such as Parkinson's disease, myoclonus dystonia, autism, amyotrophic lateral sclerosis and multiple sclerosis, major epileptic seizures or minor epileptic seizures. In one embodiment, neurological conditions are treated using encapsulated or frozen material. In alternative embodiments, for colitis patients, recurrent administration is necessary to suppress and revert to inflammatory bowel disease and irritable bowel syndrome.
In the alternative embodiments, the collected crude stools are filtered and / or homogenized, and then their bacterial cells are separated (for example, from the crude containing the fiber) through plasmopheresis, centrifugation, celtrifugation, column chromatography (for example, affinity chromatography), immunoprecipitation (for example, antibodies attached to a solid surface, such as beads or a plate). Centrifugation, including the use of a celtrifuge (for example, a Baxter model MEDIFUGE 1215) are processes that involve centrifugal force to separate mixtures. For celltrifugation, the denser components will then fly out of the turning plates while the rest of the components will migrate to the axis. The effect of the gravitational force will be increased by rotating the flattened product between the glass plates moving quickly. The centrifuge or celtrifuge can be configured in such a way that the feces will be properly diluted and placed in a spin cycle and the collection of cells will take place only peripherally in the centrifuge.
In alternative embodiments, the wild-type bacterial cells (including, for example, all (or substantially all) microbiota) separated or purified, for example, by centrifugation, celltrifugation, plasmopheresis and the like, are frozen using a protective cryo. In alternative embodiments, this material is frozen in a container, for example, a pouch, which can then be used for infusion through a colonoscope, naso-duodenal or naso-gastric tube. In alternative embodiments, it can be transferred to a location (for example, a hospital pharmacy) to be kept frozen, for example, at -20 ° C or below. Alternatively, the centrifuged material can be lyophilized; and can be used either in a solution, gels, gel tablets, pills, capsules or tablets, or suppositories, for example, to be reconstituted later as an enema or infusion established through a colonoscope.
In one embodiment the cryoprotective is trehalose. Trehalose can also function as a component after reconstitution or as an additional agent before spray drying or cryo drying.
In alternative embodiments, solutions, gel tablets, gels, pills, capsules or tablets comprising compositions of the invention (for example, isolated or purified intestinal flora or all (or substantially all) microbiota) can be taken in the long term, for example, in a long-term daily basis, for example, for one, two, three or four weeks or months, or more, to treat, stabilize, improve or prevent a chronic and / or immune condition such as, for example, persistent infection, arthritis rheumatoid, systemic lupus erythematosus, autoimmune kidney disease, for example, nephritis, severe obstruction, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and other conditions set forth here.
Preparations or cultures of the entire microbiota
In alternative embodiments, compositions (for example, manufacturing products or formulations) of the invention, comprising preparations, formulations, cultures or culture extracts or isolates comprising all or substantially the entire microbiota of an individual or species, for example, a human or other mammal . In alternative embodiments, the invention provides compositions and methods for preventing, lessening symptoms of, improving, stabilizing, or treating various infections, diseases or conditions comprising administering these preparations to all or substantially the entire microbiota (e.g., cultures or culture isolates) ); for example, administering preparations of all or substantially the entire microbiota to prevent, decrease symptoms of, improve, stabilize, or treat: spondyloarthropathy, spondyloarthritis or sacroiliitis (an inflammation of one or both sacroiliac joints); a nephritis syndrome; an inflammatory or autoimmune condition having an intestinal or intestinal component such as lupus, irritable bowel syndrome (IBS or spastic colon) or a colitis such as Ulcerative Colitis or Crohn's Colitis; constipation, autism; a degenerative neurological disease such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), or Parkinson's disease (PD); a myoclonus dystonia (for example, Steinert's disease or proximal myotonic myopathy); an autoimmune disease such as Rheumatoid Arthritis (RA) or juvenile idiopathic arthritis (JIA); chronic fatigue syndrome (including benign myalgic encephalomyelitis, chronic fatigue immune dysfunction syndrome, chronic infectious mononucleosis, epidemic myalgic encephalomyelitis); obesity; hypoglycemia, pre-diabetic syndrome, type I or type II diabetes; idiopathic thrombocytopenic purpura (ITP); acute or chronic allergic reaction such as skin rash, diaper rash, hives or a chronic hives; and / or insomnia or chronic insomnia, major epileptic seizures or minor epileptic seizures.
In alternative embodiments, the invention provides compositions and methods for administering these preparations to all or substantially the entire microbiota to prevent, decrease symptoms of, improve or treat various infections, diseases or conditions comprising, for example, constipation, an inflammatory bowel disease ( IBD), Crohn's disease, hepatic encephalopathy, entente, colitis, irritable bowel syndrome (IBS), fibromyalgia (FM), chronic fatigue syndrome (CFS), depression, attention deficit / hyperactivity disorder (ADHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), traveller's diarrhea, bacterial overgrowth of the small intestine, chronic pancreatitis, pancreatic failure, exposure to a poison or toxin or infection, toxin-mediated traveler's diarrhea, poisoning , pseudomembranous colitis, infection by Clostridium, infections by C. perfringens welchii or Clostrid ium difficile, a neurological condition, Parkinson's disease, myoclonus dystonia, autism, amyotrophic lateral sclerosis or multiple sclerosis, major epileptic seizures or minor epileptic seizures.
While the invention is not limited by any particular mechanism of action, a treated or untreated fecal sample of the invention, or a composition comprising a sample of the complete or partial intestinal flora (for example, all or substantially all of the microbiota) of the invention, or a intestinal flora partially, substantially or completely isolated or purified of the invention, when infused into a receptor (e.g., a human or animal) colonizes the intestine. In one embodiment, these preparations of the intestinal flora are made (for example, isolated) by filtering the human flora, and / or by spinning or centrifuging, plasmopheresis, celtrifuge, column chromatography (for example, affinity chromatography), or immunoprecipitation and similar, to extract the intestinal flora that is almost pure or substantially pure, or pure (for example, bacterial mass).
In an alternative embodiment, compositions of the invention are prepared by culturing all (or substantially all) microbiota grown simultaneously (e.g., all together without any pre-segregation of any particular bacterial species). In one embodiment, a sample of all (or substantially all) culture of the microbiota is formulated, for example, as a liquid, or as a dried or frozen cryo product. In one embodiment, these preparations do not contain any (or are substantially free of) non-flora material, for example, unabsorbed components normally present in a faecal sample, for example, unprepared human feces. In one embodiment, unprepared stools (e.g., human) are made into a therapeutic agent or formulation.
In one embodiment, the invention provides methods of growing an entire mammal, for example, a human, flora by taking a stool sample from a suitable donor. In one embodiment, a suitable donor is a pathogen-free individual; for example, in one aspect a sample is taken from a donor that has been classified as normal and free of any pathogens. In one embodiment, as a stand-alone therapeutic or in conjunction with other therapies, lean donor bacteria can be used to treat obesity in obese patients.
In alternative embodiments, a culture is performed for about 2, 3, 4, 5, 6, 7 or 8 or more days under total or substantially total anaerobic conditions. Standard culture procedures can be used using, for example, a non-selective gut microbiota (GMM) medium, and in one embodiment, incubated at a (human) body temperature of about 36.8 ° C. An atmosphere deprived of (or substantially deprived of) oxygen and containing nitrogen, carbon dioxide and hydrogen can be used. Different GMMs can be used with varying concentrations of the GMM composition.
Colonies or cultivated flora are then harvested through, for example, fragmentation with a sterile fragmentator. Harvested colonies or cultivated flora can be frozen, for example, at about 80 ° or below (for example, in a freezer), using, for example, a precipitated cryol such as, for example, a glycerol, a cysteine or a milk. Such cultures can then be separated to be used only once (since re-culture can cause a loss of adhesions). In one embodiment, the methods may comprise re-cultures, for example, in a lipid culture medium similar to GMM.
All of this medium can be frozen again using, for example, a glycerol with a cysteine; and in one embodiment, it can be kept frozen or freeze dried. It can produce about 108 to about 10 ¹⁰ CFUs.
In alternative embodiments, the powder, dried, frozen, dried or liquid cryo forms or other forms of the cultured bacteria (e.g., human) (e.g., all or substantially all microbiota) can be formulated and / or used or as an enema , a food, or food supplement or formulation (for example, added to a yogurt, milk, drink, flavored drink or food), or transferred as a capsule, tablet, gel tablet, or the like (for example, as a capsule coated) to recolonize or alternatively or therapeutically to colonize ”an intestinal flora.
In alternative embodiments, the cultured bacterium is added to the culture or sample or formulation of the whole (or substantially all) microbiota. For example, in one embodiment, the first administration or daily formulations initially comprise only one formulation of the entire microbiota; while in other embodiments the first administration or the initial daily formulations comprise both, the entire microbiota and the additional cultivated bacteria, for example, cultured probiotic bacteria. In alternative embodiments, less frequent formulations or dosages (which may be depending on the stage in small or large intervals, or periodic intervals, or intervals as determined by the doctor or veterinarian according to the rate of improvement, and the like) comprise only the entire the microbiota while the other embodiments comprise both, the entire microbiota bacterium and the additional cultured bacteria, for example, cultured probiotic bacteria.
In alternative embodiments, to achieve a desired effect or therapeutic result, the additional bacterium grown (for example, added to the entire microbiota) is a Bacteroides, Firmicutes and / or Bacillus thuringiensis species, which can be directly isolated from a donor, or can come from a pure culture, and the like. In alternative embodiments, a transfer of an increased amount of one or more species of the intestinal flora (for example, bacterial) is used, for example, the product of the entire transferred microbiota is increased with (is studded with) one or more additional species , for example, Bacteroides, Firmicutes and / or Bacillus thuringiensis species.
Multiple or repeated infusions or administrations
In alternative embodiments, the compositions (for example, manufacturing products or formulations) of the invention, including a treated or untreated fecal sample, or a partially, substantially or completely isolated or purified intestinal flora, or a culture of the entire human microbiota of the invention, or all (or substantially all) microbiota or combinations thereof are formulated for or calibrated for repeated or multiple transfer or infusions. In the embodiments; As alternatives to the methods of the invention, the intestinal flora partially, substantially or completely isolated or purified, for example, from all human microbiota, or all (or substantially all) microbiota, or a combination thereof, is transferred or administered through repeated administrations or infusions.
The invention in this way provides compositions and methods for treating, stabilizing or ameliorating intestinal flora infections or conditions that are difficult to permanently reverse, or for treating or ameliorating conditions characterized by intestinal flora infections that are difficult to permanently reverse. It has been found that multiple, repeated infusions can overcome infections of the intestinal flora or conditions that are difficult to permanently reverse. In alternative embodiments, in the practice of the methods and / or compositions (for example, manufacturing products or formulations) of the invention, multiple or repeated implantations of the intestinal flora (administrations, infusions) can overcome an ongoing tenacious underlying infection of the flora in an individual (for example, an animal or patient) with, for example, external bacterial and / or pathogenic strains, or a chronic condition.
With inadequate elimination of the infectious bacteria (for example, pathogenic and / or external), the original current symptoms may return. It is known that the bacterium sometimes does not divide and can live in biofilms on many moist (for example, internal) surfaces of the body. Second, the bacterium has spores that can be more difficult to eradicate at intermittent times of sporulation. There are also dormant forms of bacteria that can be intra and extra cellular where they are much more difficult to eradicate - except when the latent form is dividing. Finally, the intracellular bacteria can wait until the cell in the intestinal wall in which they are housed is shed into the lumen of the intestine, reinfecting the flora. In alternative embodiments, the multiple or repeated infusions of the gut flora of the methods of the invention can, and may be necessary, kill or otherwise inactivate the viable bacteria (for example, infectious, pathogenic and / or external) that was protected within the cell , biofilm and the like. In alternative embodiments, the multiple or repeated infusions of the intestinal flora of the methods of the invention can, and may be necessary, kill or otherwise inactivate the bacterial cells that move above the crypts near the lumen, where they are spilled into the faecal stream and reinfect the individual or patient.
Additionally, in alternative embodiments, the multiple (recurring) or repeated implantations of the intestinal flora (administrations, infusions) of the methods and / or compositions (for example, manufacturing products or formulations) of the invention are effective in preventing, stabilizing, reducing symptoms to, improve or treat individuals (for example, patients) with: spondyloarthropathy, spondyloarthritis or sacroiliitis (an inflammation of one or both sacroiliac joints); a nephritis syndrome; an inflammatory or autoimmune condition having an intestinal or intestinal component such as lupus, irritable bowel syndrome (IBS or spastic colon) or a colitis such as Ulcerative Colitis or Crohn's Colitis; constipation, autism; a degenerative neurological disease such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) or Parkinson's disease (PD); a myoclonus dystonia (for example, Steinert's disease or proximal myotonic myopathy); an autoimmune disease such as rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA); chronic fatigue syndrome (including benign myalgic encephalomyelitis, chronic fatigue immune dysfunction syndrome, chronic infectious mononucleosis, epidemic myalgic encephalomyelitis); obesity; hypoglycemia, pre-diabetic syndrome, type I or type II diabetes; idiopathic thrombocytopenic purpura (ITP); an acute or chronic allergic reaction such as skin rashes, diaper rash, hives or a chronic hives; and / or insomnia or chronic insomnia, major epileptic seizures or minor epileptic seizures.
In alternative embodiments, the invention is practiced (is performed) also through the use of the methods or compositions of the invention, including recurrent enemas from filtered human feces, recurrent infusions through a naso-duodenal (ND) or naso-gastric (NG) tube .
In alternative embodiments, the methods or compositions of the invention formulate or use a variety of formulations, for example, bacterial material from frozen stool can be suspended as an aromatized drink or placed in an ND or NG tube or inserted as an enema.
In alternative embodiments, the extracted bacteria - the 'wild types' are cryo-dried (optionally, after partial, substantial or complete purification and isolation) and formed into powder; they can then be taken, for example, as enteric coated capsules, tablets, solutions and the like.
In alternative embodiments, these 'products' of the invention are initially taken, infused or administered daily, then less and less frequently, and in some embodiments, finally once every few weeks or monthly.
In alternative embodiments the cultured bacteria can be used in addition to or with the intestinal flora partially, substantially or completely purified or isolated. For example, in one embodiment the first administration or daily initial formulations comprise only partially, substantially or completely purified or isolated intestinal flora; while in other embodiments the first administration or the initial daily formulations comprise both the intestinal flora partially, substantially or completely purified or isolated and the cultured bacteria, for example, cultured probiotic bacteria. In alternative embodiments, less frequent formulations or dosages (which may be depending on the stage in small or large intervals, or periodic intervals, or intervals as determined by the doctor or veterinarian according to the rate of improvement, and the like) comprise only the intestinal flora partially, substantially or completely purified or isolated; while in other embodiments both intestinal flora comprise partially, substantially or completely isolated or purified and cultured bacteria; or in other embodiments comprise only the cultured bacterium, for example, cultured probiotic bacteria.
In the alternative embodiments, to achieve a desired effect or therapeutic result, the bacteria grown is a Bacteroides and / or Firmicutes and / or Bacillus thuringiensis species, which can be directly isolated from a donor, or can come from a pure culture and the like. In alternative embodiments, a transfer of an increased amount of one or more species of the intestinal flora (for example, bacterial) is used, for example, the transferred product is increased with (is studded with) one or more additional species, for example, a Bacteroides and / or Firmicutes and / or Bacillus thuringiensis species.
In alternative embodiments, for adequate efficacy to be determined by the person skilled in the art, formulations are introduced daily, or not daily - but instead recurrently for extended periods of time, for example, in much higher doses. In alternative embodiments, the repeated or multiple infusion, administration or implantation protocols comprise infusions made daily for about the first 10 days, and subsequently a different second dosage or formulation daily for about 10 days, and optionally a subsequent different third daily; then optionally a different fourth dosage or formulation daily, weekly, monthly and then optionally maintaining different dosages or formulations for another transfer or infusion daily, weekly or monthly until the histology reverts to normal or another parameter or treatment goal is achieved ; for example, for the treatment of irritable bowel syndrome, colitis such as Ulcerative Colitis or Crohn's Colitis, constipation, autism, degenerative neurological diseases such as multiple sclerosis (MS), Parkinson's disease (PD), myoclonus dystonia, rheumatoid arthritis , chronic fatigue syndrome, obesity, diabetes, type II diabetes, idiopathic thrombocytopenic purpura (ITP); autoimmune diseases, chronic urticaria and / or insomnia or chronic insomnia, major epileptic seizures or minor epileptic seizures.
In alternative embodiments, infusion, administration or repeated or multiple implantations are done with: a first formulation daily by the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , or 15 days; a second daily dosage or formulation by the subsequent ^1: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days or more; then optionally a third subsequent dosage or formulation daily (for example, by the subsequent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days or more); then optionally a fourth dosage or formulation daily or weekly (for example, for subsequent 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days, weeks, months or more); and optionally then maintaining infusions weekly or monthly, for example, the histology reverts itself towards normality, or another appropriate parameter for treatment or recovery; for example, irritable bowel syndrome, colitis such as ulcerative colitis or Crohn's colitis, constipation, autism, degenerative neurological diseases such as multiple sclerosis (MS), Parkinson's disease (PD), myoclonus dystonia, rheumatoid arthritis, chronic fatigue, obesity, diabetes, type II diabetes, idiopathic thrombocytopenic purpura (ITP), autoimmune diseases, chronic urticaria and / or chronic insomnia or insomnia, major epileptic seizures or minor epileptic seizures. A person skilled in the art, for example, a doctor or veterinarian, can assess the individual's improvement and determine the exact appropriate dosage or frequency of administration in this embodiment of repeated administration of the invention.
In alternative embodiments, these exemplary protocols can also be used to infuse or ingest the cultured probiotic bacteria that would be scanned from the intestine in waves in order to resolve the issue of biofilm spores, latent forms and intracellular bacteria.
In summary, in alternative embodiments, the invention provides compositions and methods for treating, stabilizing, or ameliorating intestinal flora infections that are difficult to permanently reverse, or for treating or ameliorating conditions characterized or related to intestinal flora infections that are difficult to permanently revert or control, through multiple, repeated infusions of the intestinal flora, as described here. In alternative embodiments, the fecal microbiota transplant compositions and methods of the invention are effective under the most difficult conditions listed above in addition to conditions where a Clostridium, for example, C. difficile, is the infectious agent. In alternative embodiments, repeated or recurrent infusions are the key to achieving a cure, stabilization or prolonged remission.
Devices for transferring the compositions of the invention
The invention also provides devices for transferring compositions of the invention, for example, an exemplary transfer device is illustrated in Figures 1B. In alternative embodiments, a device of the invention may also comprise or consist of:
(b) (I) a pouch or container comprising an outlet opening operatively connected to the proximal end of a flexible tube or equivalent, wherein the pouch or container is optionally made of a material impervious to a gas or oxygen and optionally the pouch or container is made of a flexible material, or a material (or a MYLAR ™ comprising) comprising polyethylene terephthalate polyester film, and optionally the pouch or container is an intravenous type pouch (type IV), and optionally the pouch or container has a fixation that will allow the bag to be hung on a support, for example, to be positioned / hung above an endoscope, and optionally the bag or container is operationally connected via an opening or closing valve or equivalent to a negative pressure that can remove all gas or air from the bag, and optionally the bag or container is operationally connected via an opening or closing valve or equivalent to a fluid source or storage container for discharging the bag through the outlet opening, and optionally the fluid source or storage container is under positive pressure, and optionally the flexible tube or equivalent comprises at least one clip or shut-off valve 25 or single flow valve to prevent backwashing of material from the distal part to the proximal part of the tube, or from the tube back to the pouch or container;
(2) an opening or closing valve or equivalent or a screw cap plug at the distal end of the flexible flow or equivalent, and optionally a Luer snap lock for attaching a colonoscope or an endoscopic Luer lock port or equivalent, in that optionally the tip of the Luer lock is embedded in the valve, or is separate from the valve, and optionally an end of the enema tube for attachment to an enema tube or device or equivalent, in which optionally the enema tube tip is embedded in the valve, or is separate from the valve, and optionally further comprising a safety device or safety clip to close the distal opening 5 in the event that the Luer lock valve or tip, or enema tip, is lost (flying) under pressure; and (3) a pump, or portable pump, for moving material in the bag or container through the flexible tube or equivalent and outside the distal end or outside the opening or closing valve, or equivalent.
In alternative embodiments, a device of the invention further comprises a treated or untreated intestinal flora, or a partially, substantially or completely isolated intestinal flora, or a composition of the invention, for example, a partially, substantially or completely isolated or purified intestinal flora, or a composition comprising an intestinal flora substantially or completely purified from the non-fecal material of the intestinal flora, and optionally further comprising an excipient, or a fluid, a saline solution, a buffer, a buffering agent or a medium, or agar medium. fluidglucose-cellobiose (RGCA).
In one embodiment, the invention provides a pouch or container comprising treated or untreated intestinal flora, or partially, substantially or completely isolated intestinal flora, or a composition of the invention, for example, partially, substantially or completely isolated intestinal flora or purified, or a composition comprising an intestinal flora substantially or completely purified from non-fecal material of the intestinal flora, and optionally further comprising an excipient, a fluid, a saline solution, a buffer, a buffering agent or a medium, or a medium fluid-glucose-cellobiose agar (RGCA), wherein the pouch or container is structurally the same or similar to a pouch or container of a device of the invention, for example, a pouch or container comprising an outlet opening operably connected to proximal end of a flexible tube or equivalent, etc., as described above magnet.
The invention will be further described with reference to the following examples; however, it should be understood that the invention is not limited to such examples.
EXAMPLES
EXAMPLE 1: Exemplary methods of the invention
An exemplary procedure of the invention involves 5 to 10 days treatment with enemas comprising a fecal bacterial flora treated or isolated from the invention initially derived from a healthy donor. Alternatively, patients can recover after just one treatment.
In one embodiment, the best donor choice is a close relative who has been tested for a wide variety of parasitic and bacterial agents. Enemas are prepared and administered in a hospital setting to ensure all necessary precautions are taken. An exemplary probiotic infusion of the invention can also be administered through a nasogastric tube, transferring the bacteria directly to the small intestine. These two methods can be combined to achieve a desired result. Regular checkups must be requested after the year following the procedure.
In one embodiment, the autologous faecal sample is provided by the patient prior to medical treatment, and is stored in a freeze dried, freeze-dried refrigerator or equivalent. The patient must subsequently develop an infection, for example, a C. difficile infection, the sample is prepared (extracted) with saline and filtered. The filtrate can be cryo-dried and the resulting solid wrapped in a capsule, for example, an enteric coated capsule. The administration of the capsules can recover the patient's own colon flora and fight infection, for example, C, difficile. In one embodiment, samples are transferred to the duodenum via a nasal probe.
In one embodiment, a method of the invention comprises the collection of healthy donors of fresh human flora (feces), bringing it to a centralized institution, processing it so that it will be given an extended life, checking for pathogens, maintaining temperature control for reducing the bacterial metabolic activity and controlling oxygen shock, developing a standardized homogenized flora storage unit, and sending the flora to distant hospitals to treat patients with, for example, acute pseudomembranous colitis, severe C. difficile infection, septicemia or other comparable conditions.
In one embodiment, the product of the invention is a modified stool composition. Feces need to be collected and promptly placed in an anaerobic container that extracts air, possibly with substances that adsorb and absorb oxygen or can be evacuated and filled with nitrogen or other gas that is either inert or will not damage the anaerobic flora. It must be kept in an aesthetically acceptable container that will not leak feces or the gas that is producing the anaerobic situation. Once transferred to the 'central bank ¹ faeces may be stored in a cold atmosphere to slow metabolism, but not be frozen to prevent the destruction of the expansion of the water contained in the bacterial cells in the stool.
In one embodiment, also oxidants and / or substances such as glycerol are added to help stabilize the bacteria in the cold and prevent it from being destroyed during storage and during transport.
In one embodiment the product is stored / contained as (in) a volume between about 10 cc and 3 liters of feces. In one embodiment, the product is stored in a (as a) 300 cc container (or quantity) and kept in a suitable oxygen-resistant material, for example, plastic, a gas impenetrable or gas-resistant polyethylene terephthalate polyester film oxygen (for example, in metallized form), or MYLAR ™ metallized, or MYLAR ™ aluminized, which can be attached to a pump through a set that will be attached to the colonoscope and administered through a colonoscopy in a distal small intestine or in the upper colon / terminal ileum to overcome Clostridium difficile infection.
Central Flora Supply Institution or Bank
In one embodiment, an institution works to supply human flora as follows:
1. The faeces will be collected in special containers and kept anaerobically cooled until they have reached the central flora processing unit.
2. In a processing unit, special additives will be added including glycerol, possibly antioxidants and other special preservatives and kept cool, homogenized and dispensed in appropriate intravenous bags, but with somehow thicker product such as a polyester terephthalate film. gas-impenetrable polyethylene, or an aluminized MYLAR ™. This will prevent oxygen from being transferred, nitrogen from escaping and the smell from being detected by the management team. The bags will then be kept at a temperature that does not allow the bacteria to freeze and be ready for transport in refrigerators to hospitals that will be performing the fecal transplant.
3. The bag will be provided with a set set, so that it does not have to be handled by the hospital staff. A 'blood type' pump with a single flow valve will be attached to it. In the intravenous type bag (type IV) there will be fixations that will be able to allow the bag to be hung in an IV fluid holder and to be positioned / hung above the endoscope. The endoscopist will then remove the screw cap plug and attach the tip of the Luer lock to the endoscopic Luer lock port to be infused through the biopsy forceps channel at the tip of the colonoscope or endoscope. A safety device would be attached in case the tip flies under pressure. The air will then be drawn out of the tube as the product is allowed to flow under the 'given set' with pressure mechanisms throughout the set, with the air removed, and then the faeces will be administered using the delivery pump into the patients' colon. and discharged, for example, with some saline solution.
4. The endoscopist will then remove the colonoscope, turn the patient 'upside down' to allow air and liquid to be absorbed and prevent the patient from defecating too early. This will allow the bacterium to recover its temperature, begin to attach itself to the intestinal walls as described, for example, by Grehan et al., J. of Clinical Gastroenterology, Sept. 2010.
A number of embodiments of the invention have been described. However, it will be understood that several modifications can be made without departing from the spirit and scope of the invention. In this way, other embodiments 5 are within the scope of the following claims.

权利要求:
Claims (26)
[1]
1. Method, characterized by understanding: receiving in a central location an unfrozen stool sample from a donor, where the stool sample is inside a stool collection device; testing the stool sample for pathogens; mixing the stool sample with a cryoprotectant to form a mixture; and homogenizing the mixture to produce a composition comprising viable bacteria from the stool sample.
[2]
Method according to claim 1, characterized in that it further comprises filtering the composition to produce a filtrate.
[3]
Method according to claim 2, characterized in that it further comprises the selective removal of bacteria from the filtrate to produce a composition comprising bacterial species of the phylum Firmicutes.
[4]
Method according to claim 3, characterized in that the selectively removed bacteria comprise Bacteroids.
[5]
5. Method according to claim 3, characterized in that the composition comprises a bacterial population consisting essentially of bacterial phylum Firmicutes species.
[6]
6. Method according to claim 1, characterized by the fact that the cryoprotectant comprises trehalose.
[7]
7. Method according to claim 1, characterized by the fact that said mixture further comprises mixing the stool sample with an antioxidant.
Petition 870190065468, of 7/11/2019, p. 8/175
2/4
[8]
8. Method according to claim 1, characterized by the fact that said mixture further comprises mixing the stool sample with cysteine.
[9]
9. Method, according to claim 2, characterized by the fact that it also comprises the freeze-drying of the filtrate.
[10]
10. Method according to claim 9, characterized in that it further comprises encapsulating the lyophilized filtrate in a vehicle.
[11]
11. Method according to claim 10, characterized by the fact that the encapsulated filtrate is in a gradual-release capsule.
[12]
12. Method, characterized by understanding: receiving a non-frozen stool sample from a donor in a central location, in which the stool sample is inside a stool collection device and in which the donor has been pre-screened for infectious agents; mixing the stool sample with a fluid to form a mixture, wherein the fluid comprises a cryoprotectant; and homogenizing the mixture to produce a composition comprising viable bacteria from the stool sample.
[13]
13. Method according to claim 12, characterized in that it further comprises filtering the composition to produce a filtrate.
[14]
14. Method according to claim 13, characterized in that it further comprises the selective removal of bacteria from the filtrate to produce a composition comprising phylum Firmicutes bacterial species.
[15]
15. Method, according to claim 13, characterized by the fact that it also comprises the freeze-drying of the filtrate.
Petition 870190065468, of 7/11/2019, p. 9/175
1/4
[16]
16. Method, according to claim 15, characterized by the fact that it further comprises encapsulating the lyophilized filtrate in a vehicle.
[17]
17. Method according to claim 1, characterized by the fact that an interior of the stool collection device is anaerobic.
[18]
18. Method, according to claim 9, characterized by the fact that it also comprises sending the freeze-dried filtrate to a remote location.
[19]
19. Method according to claim 12, characterized by the fact that an interior of the stool collection device is anaerobic.
[20]
20. Method, according to claim 15, characterized by the fact that it further comprises sending the lyophilized filtrate to a remote location.
[21]
21. Method, according to claim 2, characterized by the fact that the stool sample is kept below room temperature.
[22]
22. Method according to claim 2, characterized by the fact that the filtration separates bacteria from microscopic fiber.
[23]
23. Method according to claim 2, characterized by the fact that filtration separates bacteria from raw particulate matter.
[24]
24. Method, according to claim 13, characterized by the fact that the stool sample is kept below room temperature.
[25]
25. Method according to claim 13, characterized by the fact that filtration separates bacteria from microscopic fiber.
Petition 870190065468, of 7/11/2019, p. 10/175
4/4
[26]
26. Method according to claim 13, characterized by the fact that the filtration separates bacteria from the raw particulate material.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10617724B2|2020-04-14|Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

同族专利:

---

公开号 | 公开日

---

US10610551B2|2020-04-07|

---

EP3701958A1|2020-09-02|

---

US11065284B2|2021-07-20|

---

NZ618935A|2014-03-28|

---

US20180369295A1|2018-12-27|

---

KR102216603B1|2021-02-17|

---

US10278997B2|2019-05-07|

---

US11173183B2|2021-11-16|

---

AU2011286165B2|2016-10-20|

---

EP3311825A1|2018-04-25|

---

RU2013109251A|2014-09-10|

---

US20130195804A1|2013-08-01|

---

CA2807242C|2017-05-02|

---

US11207356B2|2021-12-28|

---

US10064899B1|2018-09-04|

---

KR20170075809A|2017-07-03|

---

US20190282631A1|2019-09-19|

---

KR20130098320A|2013-09-04|

---

JP2013537531A|2013-10-03|

---

US20220031764A9|2022-02-03|

---

US20190046589A1|2019-02-14|

---

JP2016199581A|2016-12-01|

---

US11103541B2|2021-08-31|

---

US20180228849A1|2018-08-16|

---

BR112013002667A2|2016-05-31|

---

CN103124559B|2017-03-29|

---

US20190015462A1|2019-01-17|

---

US20190343897A1|2019-11-14|

---

US10328107B2|2019-06-25|

---

US10463702B2|2019-11-05|

---

US10987385B2|2021-04-27|

---

US10857188B2|2020-12-08|

---

WO2012016287A2|2012-02-09|

---

US20210052673A1|2021-02-25|

---

MX344831B|2017-01-04|

---

US20210205375A1|2021-07-08|

---

EP3424515A3|2019-06-19|

---

US20190381114A1|2019-12-19|

---

US9308226B2|2016-04-12|

---

JP2018021052A|2018-02-08|

---

MX2013001331A|2013-06-03|

---

US10617724B2|2020-04-14|

---

US20200397834A1|2020-12-24|

---

US20190216860A1|2019-07-18|

---

US10675309B2|2020-06-09|

---

US10849937B2|2020-12-01|

---

JP6606689B2|2019-11-20|

---

US20180036351A1|2018-02-08|

---

EP2600877A2|2013-06-12|

---

US20180256652A1|2018-09-13|

---

SG187713A1|2013-03-28|

---

AU2011286165A1|2013-03-07|

---

US20220023356A1|2022-01-27|

---

EP2600877A4|2014-05-07|

---

IL224527A|2016-11-30|

---

NZ607043A|2015-05-29|

---

CN103124559A|2013-05-29|

---

CA2807242A1|2012-02-09|

---

US20200397833A1|2020-12-24|

---

US20160296568A1|2016-10-13|

---

US20190015460A1|2019-01-17|

---

US11129859B2|2021-09-28|

---

US20200108104A1|2020-04-09|

---

WO2012016287A3|2012-11-29|

---

US10022406B2|2018-07-17|

---

EP3424515A2|2019-01-09|

---

US9962413B2|2018-05-08|

---

US20200289584A1|2020-09-17|

---

US20190015461A1|2019-01-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

FR1275M|1962-05-02|Rene Roger|Medicinal product based on live colibacilli.|

---

DE1118403B|1960-01-27|1961-11-30|Hoechst Ag|Method for obtaining antitumor spores|

---

BE634858A|1962-07-19|1900-01-01|

---

FR2828M|1963-03-01|1964-11-02|Lucien Nouvel|Drug containing antibiotic-resistant colibacilli.|

---

FR5528M|1965-10-01|1967-11-13|

---

GB1271674A|1968-07-09|1972-04-26|Nisshin Flour Milling Co|Process and preparation for treating diarrhoea in pigs|

---

SE371209B|1969-10-13|1974-11-11|Cernelle Ab|

---

DE2134179A1|1971-07-09|1973-01-25|Rolf Dr Schuler|Prepns contg several bifidobacterium species - for normalizing intestinal flora|

---

FR2244464B1|1973-06-26|1976-09-03|Serozym Laboratoires|

---

US3913564A|1974-04-24|1975-10-21|Richard C Freshley|Anaerobic specimen collecting and transporting device|

---

US4098728A|1976-01-02|1978-07-04|Solomon Rosenblatt|Medical surgical sponge and method of making same|

---

US4335107A|1978-06-05|1982-06-15|Snoeyenbos Glenn H|Mixture to protect poultry from salmonella|

---

CH637297A5|1978-12-05|1983-07-29|Nestle Sa|MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.|

---

US4309782A|1980-09-11|1982-01-12|Esteban Paulin|Device for collecting fecal specimens|

---

US4536409A|1981-01-23|1985-08-20|American Can Company|Oxygen scavenger|

---

US4452779A|1982-02-03|1984-06-05|Cockerill Vernon|Composition and method of treating lactating mammals|

---

FI840816A0|1984-03-01|1984-03-01|Farmos Oy|BAKTERIEPREPARAT|

---

JPH0564127B2|1984-06-19|1993-09-14|Advance Kk|

---

US4892731A|1986-12-11|1990-01-09|Tadashi Arai|Biological intestinal antiseptics|

---

IL86859A|1987-07-10|1991-12-15|E Z Em Inc|Aqueous cathartic solution containing inorganic salts|

---

US4948734A|1987-08-12|1990-08-14|Mycogen Corporation|Novel isolates of bacillus thuringiensis having activity against nematodes|

---

JPH0167192U|1987-10-26|1989-04-28|

---

US5443826A|1988-08-02|1995-08-22|Borody; Thomas J.|Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli|

---

EP0433299B1|1988-08-02|1998-05-06|Gastro Services Pty. Limited |Treatment of gastro-intestinal disorders|

---

US5213807A|1990-05-03|1993-05-25|Chemburkar Pramod B|Pharmaceutical composition containing ibuprofen and a prostaglandin|

---

JP2961184B2|1990-05-07|1999-10-12|ミヤリサン株式会社|Pharmaceutical composition for prevention and treatment of Clostridium difficile diarrhea and pseudomembranous colitis|

---

US5266315A|1990-05-07|1993-11-30|Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho|Composite for Clostridium difficile diarrhea and pseudomembranous colitis|

---

GB9107305D0|1991-04-08|1991-05-22|Unilever Plc|Probiotic|

---

JP3047143B2|1992-04-24|2000-05-29|堀井薬品工業株式会社|Composition for intestinal lavage and intestinal lavage|

---

JP3850891B2|1994-03-01|2006-11-29|ゼリア新薬工業株式会社|Composition having a laxative effect|

---

JPH07242557A|1994-03-03|1995-09-19|Ss Pharmaceut Co Ltd|Evacuant composition containing lactic acid bacterium|

---

US6984513B2|1994-03-03|2006-01-10|The Board Of Trustees Of The Leland Stanford Junior University|Anaerobe targeted enzyme-mediated prodrug therapy|

---

ES2099056T3|1994-05-26|1998-04-01|Bracco Spa|STRAINS OF LACTOBACILLUS OF HUMAN ORIGIN, ITS COMPOSITIONS AND USES OF THEM.|

---

US5599795A|1994-08-19|1997-02-04|Mccann; Michael|Method for treatment of idiopathic inflammatory bowel disease |

---

AUPM864894A0|1994-10-07|1994-11-03|Borody, Thomas Julius|Treatment of bowel-dependent neurological disorders|

---

US5800821A|1995-03-10|1998-09-01|New England Medical Center Hospitals, Inc.|Bacterial spores as a heat stable vaccine delivery system|

---

US7048906B2|1995-05-17|2006-05-23|Cedars-Sinai Medical Center|Methods of diagnosing and treating small intestinal bacterial overgrowth and SIBO-related conditions|

---

US5858356A|1995-12-21|1999-01-12|Abbott Laboratories|Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals|

---

US5902578A|1996-03-25|1999-05-11|Abbott Laboratories|Method and formula for the prevention of diarrhea|

---

US5837238A|1996-06-05|1998-11-17|Biogaia Biologics Ab|Treatment of diarrhea|

---

US6087386A|1996-06-24|2000-07-11|Merck & Co., Inc.|Composition of enalapril and losartan|

---

WO1998013068A1|1996-09-26|1998-04-02|Vladimir Borisovich Kuperman|Medicinal prophylactic 'trisan'|

---

US5948787A|1997-02-28|1999-09-07|Alza Corporation|Compositions containing opiate analgesics|

---

US6162464A|1997-03-31|2000-12-19|Inkine Pharmaceutical, Inc.|Non-aqueous colonic purgative formulations|

---

US7374753B1|1997-06-03|2008-05-20|Ganeden Biotech, Inc.|Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS|

---

US5951977A|1997-10-14|1999-09-14|The United States Of America, As Represented By The Secretary Of Agriculture|Competitive exclusion culture for swine|

---

US6428783B1|1998-03-11|2002-08-06|Medtech Center, Inc.|Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men|

---

US5902743A|1998-03-20|1999-05-11|Wisconsin Alumni Research Foundation|Probiotic bifidobacterium strain|

---

US6649397B1|1998-05-06|2003-11-18|Orient Green Co., Ltd.|Microbial culture liquors containing microorganisms differing in characteristics and living in symbiosis and metabolites thereof, carriers and adsorbents containing the active components of the culture liquors and utilization of the same|

---

US6368591B2|1998-05-15|2002-04-09|Shanghai Sine Pharmaceutical Corporation Ltd.|Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof|

---

AT407008B|1998-08-06|2000-11-27|Viernstein Helmut Dr|FORMULATIONS WITH PROBIOTALLY EFFECTIVE MICROORGANISMS|

---

US6461607B1|1998-08-24|2002-10-08|Ganeden Biotech, Inc.|Probiotic, lactic acid-producing bacteria and uses thereof|

---

WO2000015760A1|1998-09-17|2000-03-23|North American Vaccine, Inc.|Streptococcal c beta protein compositions|

---

EP1005863A1|1998-12-04|2000-06-07|Synthelabo|Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof|

---

NZ512275A|1998-12-11|2003-11-28|Urex Biotech Inc|Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens|

---

US6245740B1|1998-12-23|2001-06-12|Amgen Inc.|Polyol:oil suspensions for the sustained release of proteins|

---

ID29150A|1999-01-15|2001-08-02|Entpr Ireland Cs|USE OF LACTOBACILLUS SALIVARIUS|

---

AU754712B2|1999-02-26|2002-11-21|Shionogi & Co., Ltd.|Chewable soft capsules having improved administration properties and process for producing the same|

---

WO2000066005A1|1999-05-03|2000-11-09|Exact Laboratories, Inc.|Stool specimen collector|

---

JP3478773B2|1999-12-21|2003-12-15|日東薬品工業株式会社|Viable bacteria composition|

---

FR2808689B1|2000-05-11|2004-09-03|Agronomique Inst Nat Rech|USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS|

---

US20040170617A1|2000-06-05|2004-09-02|Finegold Sydney M.|Method of treating diseases associated with abnormal gastrointestinal flora|

---

US20040062757A1|2001-06-05|2004-04-01|Finegold Sydney M.|Method of testing gastrointestinal diseases associated with species of genus clostridium|

---

US20020013270A1|2000-06-05|2002-01-31|Bolte Ellen R.|Method for treating a mental disorder|

---

US6756032B1|2000-07-12|2004-06-29|The Procter & Gamble Company|Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge|

---

AU7236901A|2000-07-17|2002-01-30|Hansens Lab|Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments|

---

AUPQ899700A0|2000-07-25|2000-08-17|Borody, Thomas Julius|Probiotic recolonisation therapy|

---

US7214370B2|2000-12-18|2007-05-08|Probiohealth, Llc|Prebiotic and preservative uses of oil-emulsified probiotic encapsulations|

---

US6790453B2|2001-03-14|2004-09-14|Mccormick & Company, Inc.|Encapsulation compositions and process for preparing the same|

---

US7815956B2|2001-04-27|2010-10-19|Pepsico|Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products|

---

JP4756823B2|2001-06-01|2011-08-24|ポーゼンインコーポレイテッド|Pharmaceutical composition for coordinated delivery of NSAIDs|

---

JPWO2003004003A1|2001-07-05|2004-10-21|湧永製薬株式会社|Soft capsule|

---

PE20030284A1|2001-07-26|2003-05-01|Alimentary Health Ltd|BIFIDOBACTERIUM STRAINS|

---

US20030092724A1|2001-09-18|2003-05-15|Huaihung Kao|Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic|

---

GB0124580D0|2001-10-12|2001-12-05|Univ Reading|New composition|

---

WO2003084520A2|2002-04-05|2003-10-16|Euro-Celtique S.A.|Pharmaceutical preparation containing oxycodone and naloxone|

---

CA2391422A1|2002-07-12|2004-01-12|David William Molloy|Rifampin and doxycycline, and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...|

---

US7270946B2|2002-10-04|2007-09-18|Organ Recovery Systems, Inc.|Method for treatment of cellular materials with sugars prior to preservation|

---

IL152127D0|2002-10-06|2003-05-29|Bio Balance Corp|Probiotic compositions for the treatment of inflammatory bowel disease|

---

AU2004265511A1|2003-08-18|2005-02-24|The Bio Balance Corporation|A stable liquid probiotic composition, preparation and applications thereof|

---

US20060177424A1|2003-08-29|2006-08-10|Cobb Mark L|Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions|

---

US7759105B2|2003-08-29|2010-07-20|Cobb & Company, Llp|Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions|

---

US8192733B2|2003-08-29|2012-06-05|Cobb & Associates|Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions|

---

US7749509B2|2003-08-29|2010-07-06|Cobb And Company, Llp|Treatment of autism using probiotic composition|

---

US8016816B2|2003-09-09|2011-09-13|Convatec Technologies Inc.|Fecal management appliance and method and apparatus for introducing same|

---

US7541091B2|2004-05-18|2009-06-02|M & G Usa Corporation|Compartmentalized resin pellets for oxygen scavenging|

---

US20060275223A1|2005-06-02|2006-12-07|Burr James B|Erythritol compositions for teeth and gums|

---

EP1800688A1|2004-08-05|2007-06-27|Anidral S.R.L.|Folic acid producing bifidobacterium bacterial strains, formulations and use thereof|

---

DE602004007813T2|2004-08-05|2008-04-17|Anidral S.R.L.|FOLIC ACID PRODUCING BIFIDOBACTERIUM BACTERIA STRAINS, THEIR FORMULATIONS AND USE|

---

US20060076536A1|2004-09-29|2006-04-13|Barshied Scott R|Oxygen scavenging pharmaceutical package and methods for making same|

---

US20060115465A1|2004-10-29|2006-06-01|Macfarlane George|Treatment of gastrointestinal disorders|

---

JP4811760B2|2004-12-27|2011-11-09|独立行政法人農業・食品産業技術総合研究機構|Enterobacteria and its utilization to improve equol production by utilization of daidzein|

---

JP5073174B2|2005-03-18|2012-11-14|木村産業株式会社|Method for producing tablets containing viable bacteria agent, digestive enzyme agent and both|

---

CA2609007A1|2005-05-20|2006-11-30|Dow Global Technologies Inc.|Oral drug compliance monitoring using radio frequency identification tags|

---

US8147445B2|2005-06-14|2012-04-03|C.B. Fleet Company Inc.|Enema dispenser|

---

TWI362949B|2005-09-13|2012-05-01|Bion Tech Inc|Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up|

---

SI1962873T1|2005-12-14|2013-10-30|Oxthera Intellectual Property Ab|Pharmaceutical compositions comprising oxalate-reducing bacteria|

---

EP1970055B1|2005-12-29|2010-11-24|Osmotica Kereskedelmi És Szolgáltató Kft|Multi-layered tablet with triple release combination|

---

JP5006567B2|2006-04-14|2012-08-22|花王株式会社|Oral solid formulation|

---

US7998510B2|2006-08-17|2011-08-16|C. B. Fleet Company, Inc.|Low dose colonic cleansing system|

---

JP2008106066A|2006-09-25|2008-05-08|Tashiro Yasuaki|Composition containing saponin and viable bacterium|

---

DE602007007355D1|2006-12-04|2010-08-05|Du Pont|COATING COMPOSITION OF ACRYLIC POLYOL|

---

DE102006062250A1|2006-12-22|2008-06-26|Roland Saur-Brosch|Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort|

---

US7645801B2|2007-01-29|2010-01-12|Alaven Pharmaceutical Llc|Reduced irritant enema for treatment of inflammatory bowel disease |

---

SI2136825T1|2007-03-01|2014-04-30|Probi Ab|Use of lactobacillus plantarum for increasing bacterial diversity|

---

MX2009010418A|2007-03-28|2010-02-18|Alimentary Health Ltd|Probiotic bifidobacterium strains.|

---

NZ580005A|2007-03-28|2012-03-30|Alimentary Health Ltd|Probiotic bifidobacterium strain 41382|

---

JP2008245569A|2007-03-30|2008-10-16|Kirin Holdings Co Ltd|Lactobacillus composition having high antiallergic activity and method for producing this lactobacillus|

---

US8091582B2|2007-04-13|2012-01-10|Cla-Val Co.|System and method for hydraulically managing fluid pressure downstream from a main valve between set points|

---

AU2008258596B2|2007-06-04|2013-02-14|Egalet Ltd|Controlled release pharmaceutical compositions for prolonged effect|

---

CN101686931B|2007-06-06|2013-06-19|巴斯夫欧洲公司|Pharmaceutical formulation for the production of chewable tablets and lozenges|

---

CN101707930B|2007-06-06|2013-10-30|巴斯夫欧洲公司|Pharmaceutical formulation for production of rapidly disintegrating tablets|

---

ES2388494T3|2007-07-27|2012-10-15|Cargill, Incorporated|Micronization of Polyols|

---

EP2030623A1|2007-08-17|2009-03-04|Nestec S.A.|Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria|

---

EP2183318B1|2007-08-31|2012-03-07|Invista Technologies S.A R.L.|Oxygen scavenging plastic compositions|

---

WO2009041651A1|2007-09-27|2009-04-02|Mitsubishi Tanabe Pharma Corporation|Rapidly disintegrating solid preparation|

---

EP2572705B1|2007-10-01|2017-09-13|Laboratorios Lesvi, S.L.|Orodispersible tablets|

---

US20100222311A1|2007-10-19|2010-09-02|Purdue Research Foundation|Solid formulations of crystalline compounds|

---

JP5327984B2|2007-10-20|2013-10-30|ユニベルシテ・ド・リエージュ|Bifidobacterium species|

---

WO2009055362A1|2007-10-26|2009-04-30|Moore Brenda E|Probiotic compositions and methods for inducing and supporting weight loss|

---

JP5258268B2|2007-11-19|2013-08-07|フロイント産業株式会社|Method for producing spherical particles|

---

WO2009084678A1|2007-12-28|2009-07-09|Sawai Pharmaceutical Co., Ltd.|Oral cavity disintegrating tablet and method of producing the same|

---

CN101496819A|2008-01-31|2009-08-05|青岛东海药业有限公司|Eubacterium, Clostridium preparation and use thereof|

---

KR100913405B1|2008-03-25|2009-08-21|광주과학기술원|Compositions for preventing or treating th2-mediated immune diseases|

---

WO2009149149A1|2008-06-04|2009-12-10|Trustees Of Dartmouth College|Prevention or treatment of immune-relevant disease by modification of microfloral populations|

---

SI2350096T1|2008-10-02|2020-08-31|Salix Pharmaceuticals, Ltd.|Methods of treating hepatic encephalopathy|

---

ES2610829T3|2009-11-11|2017-05-03|Alimentary Health Limited|Bifidobacterium strain|

---

US20100178413A1|2008-12-17|2010-07-15|Mark Gorris|Food-based Supplement Delivery System|

---

WO2010103132A1|2009-03-10|2010-09-16|Hero España, S.A.|Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk|

---

US20100255231A1|2009-04-01|2010-10-07|Multisorb Technologies, Inc.|Oxygen scavenging films|

---

CN102414310B|2009-04-30|2015-05-06|阿克图杰尼斯公司|Cryoprotectants for freeze drying of lactic acid bacteria|

---

US20100285164A1|2009-05-11|2010-11-11|Jrs Pharma|Orally Disintegrating Excipient|

---

US20120064133A1|2009-05-28|2012-03-15|Ishwar Chauhan|Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations|

---

CN201441672U|2009-07-14|2010-04-28|赵伟华|Disposable enema device|

---

US20110045222A1|2009-08-19|2011-02-24|Eastman Chemical Company|Oxygen-scavenging polymer blends suitable for use in packaging|

---

US20110059168A1|2009-09-09|2011-03-10|Ang Sam|Method for correcting intestinal glutamine synthetase deficiency|

---

GB0916335D0|2009-09-17|2009-10-28|Martin W J|Medicaments|

---

US20110081320A1|2009-10-06|2011-04-07|Nubiome, Inc.|Treatment/Cure of Autoimmune Disease|

---

WO2011046616A2|2009-10-15|2011-04-21|New York University|Methods for modulating bacterial infection|

---

US20110218216A1|2010-01-29|2011-09-08|Kumaravel Vivek|Extended release pharmaceutical composition of donepezil|

---

US7888062B1|2010-02-01|2011-02-15|Microbios, Inc.|Process and composition for the manufacture of a microbial-based product|

---

US9492487B2|2010-02-01|2016-11-15|Matthew Ryan Garner|Microbial product containing multiple microorganisms|

---

AU2011209940B2|2010-02-01|2015-08-20|Mikrobex Inc.|Bacteriotherapy for clostridium difficile colitis|

---

US8853269B2|2010-02-04|2014-10-07|Copperhead Chemical Company Inc.|Composition and method for treating infections and promoting intestinal health|

---

MX2012010482A|2010-03-10|2013-03-12|Nogra Pharma Ltd|Compositions for colon lavage and methods of making and using same.|

---

US9707207B2|2010-05-26|2017-07-18|The United States Of America As Represented By The Department Of Veterans Affairs|Method for diagnosing, preventing, and treating neurological diseases|

---

WO2011151941A1|2010-06-04|2011-12-08|国立大学法人東京大学|Composition having activity of inducing proliferation or accumulation of regulatory t cell|

---

US20120020941A1|2010-07-26|2012-01-26|Suomen Punainen Risti Veripalvelu|Use of blood group status iii|

---

WO2012013861A2|2010-07-26|2012-02-02|Suomen Punainen Risti Veripalvelu|Use of blood group status iii|

---

RU2013109251A|2010-08-04|2014-09-10|Томас Джулиус БОРОДИ|COMPOSITIONS FOR TRANSPLANTATION OF FEKAL FLORA AND METHODS FOR THEIR RECEIVING AND APPLICATION AND DEVICES FOR THEIR DELIVERY|

---

WO2012045150A1|2010-10-04|2012-04-12|British Columbia Cancer Agency Branch|Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer|

---

PT3072524T|2010-10-07|2018-04-23|California Inst Of Techn|Probiotic therapies for autism|

---

US20150374761A1|2011-03-09|2015-12-31|Regents Of The University Of Minnesota|Freeze dried fecal microbiota for use in fecal microbial transplantation|

---

ES2636439T3|2011-03-09|2017-10-05|Regents Of The University Of Minnesota|Compositions and methods for colon microbiota transplantation|

---

EP2744890A4|2011-09-14|2015-07-08|Univ Kingston|Method for treatment of disorders of the gastrointestinal system|

---

CA2850437A1|2011-10-11|2013-04-18|Achim Biotherapeutics Ab|Composition comprising anaerobically cultivated human intestinal microbiota|

---

EP3569690A1|2011-12-01|2019-11-20|The University of Tokyo|Human-derived bacteria that induce proliferation or accumulation of regulatory t cells|

---

US9176026B2|2011-12-15|2015-11-03|Pureflora, Inc.|Device for the collection, refinement, and administration of gastrointestinal microflora|

---

WO2013166336A1|2012-05-02|2013-11-07|Charles River Laboratories, Inc.|Viability staining method|

---

WO2013176774A1|2012-05-25|2013-11-28|Arizona Board Of Regents|Microbiome markers and therapies for autism spectrum disorders|

---

EP2890808A4|2012-08-29|2016-09-28|California Inst Of Techn|Diagnosis and treatment of autism spectrum disorder|

---

US8906668B2|2012-11-23|2014-12-09|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|

---

CA2896795A1|2012-11-26|2014-05-30|Thomas Julius Borody|Compositions for the restoration of a fecal microbiota and methods for making and using them|

---

CN110917220A|2013-02-04|2020-03-27|赛里斯治疗公司|Therapeutic compositions and methods of use thereof|

---

WO2014152484A1|2013-03-14|2014-09-25|Regents Of The University Of Minnesota|Freeze dried fecal microbiota for use in fecal microbial transplantation|

---

US9907755B2|2013-03-14|2018-03-06|Therabiome, Llc|Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents|

---

EP2991649B1|2013-04-30|2020-06-03|Thomas Julius Borody|Compositions for treating obsessive-compulsive disorder|

---

ES2673581T3|2013-06-05|2018-06-22|Rebiotix, Inc.|Microbiota Restoration Therapy , compounds and manufacturing methods|

---

US9511100B2|2013-06-05|2016-12-06|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

US9764019B2|2013-07-09|2017-09-19|Vedanta Biosciences, Inc.|Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease|

---

WO2015051323A1|2013-10-03|2015-04-09|Trustees Of The University Of Pennsylvania|Compositions comprising a defined microbiome and methods of use thereof|

---

WO2015077794A1|2013-11-25|2015-05-28|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|

---

US9956282B2|2013-12-16|2018-05-01|Seres Therapeutics, Inc.|Bacterial compositions and methods of use thereof for treatment of immune system disorders|

---

EP3107553B1|2014-02-18|2021-12-01|Universitätsklinikum Jena|Methods and compositions for intestinal microenvironment transfer|

---

SE1550189A1|2015-02-19|2016-08-20|Achim Biotherapeutics Ab|Therapeutic and prophylactic composition produced by microbiota|

---

JP6692897B2|2015-05-14|2020-05-13|クレストヴォ・ホールディングス・エルエルシー|Compositions for implanting stool flora, methods of preparing and using same, and devices for delivering same|

---

BR112017024777A2|2015-05-22|2018-08-07|Univ Arizona State|use of a pharmaceutical composition and a non-absorbable antibiotic for treating autistic spectrum disorder cross reference to related applications?|

---

WO2017075098A1|2015-10-26|2017-05-04|Crestovo Llc|Compositions and methods for fecal microbiota-related therapy|

---

GB2557823A|2016-03-04|2018-06-27|Univ California|Microbial consortium and uses thereof|AUPQ899700A0|2000-07-25|2000-08-17|Borody, Thomas Julius|Probiotic recolonisation therapy|

---

AU2011209940B2|2010-02-01|2015-08-20|Mikrobex Inc.|Bacteriotherapy for clostridium difficile colitis|

---

RU2013109251A|2010-08-04|2014-09-10|Томас Джулиус БОРОДИ|COMPOSITIONS FOR TRANSPLANTATION OF FEKAL FLORA AND METHODS FOR THEIR RECEIVING AND APPLICATION AND DEVICES FOR THEIR DELIVERY|

---

US20150374761A1|2011-03-09|2015-12-31|Regents Of The University Of Minnesota|Freeze dried fecal microbiota for use in fecal microbial transplantation|

---

ES2636439T3|2011-03-09|2017-10-05|Regents Of The University Of Minnesota|Compositions and methods for colon microbiota transplantation|

---

JP6193850B2|2011-06-19|2017-09-06|アボゲン，インコーポレイティド|Devices, solutions and methods for sample collection|

---

GB201117313D0|2011-10-07|2011-11-16|Gt Biolog Ltd|Bacterium for use in medicine|

---

US9176026B2|2011-12-15|2015-11-03|Pureflora, Inc.|Device for the collection, refinement, and administration of gastrointestinal microflora|

---

US8906668B2|2012-11-23|2014-12-09|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|

---

CA2896795A1|2012-11-26|2014-05-30|Thomas Julius Borody|Compositions for the restoration of a fecal microbiota and methods for making and using them|

---

US10973861B2|2013-02-04|2021-04-13|Seres Therapeutics, Inc.|Compositions and methods|

---

CN110917220A|2013-02-04|2020-03-27|赛里斯治疗公司|Therapeutic compositions and methods of use thereof|

---

CN103330961B|2013-02-08|2016-06-08|南京法迈特科技发展有限公司|A kind of medical cavity content target component reclaims apparatus|

---

JP2016519664A|2013-03-15|2016-07-07|セレス セラピューティクス インコーポレイテッド|Microbial composition and method based on network|

---

GB201306536D0|2013-04-10|2013-05-22|Gt Biolog Ltd|Polypeptide and immune modulation|

---

US9511100B2|2013-06-05|2016-12-06|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

CA2928652A1|2015-05-08|2016-11-08|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

US9694039B2|2013-06-05|2017-07-04|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

US9782445B2|2013-06-05|2017-10-10|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

US10383901B2|2013-06-05|2019-08-20|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

ES2673581T3|2013-06-05|2018-06-22|Rebiotix, Inc.|Microbiota Restoration Therapy , compounds and manufacturing methods|

---

US9511099B2|2013-06-05|2016-12-06|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|

---

WO2015077794A1|2013-11-25|2015-05-28|Seres Health, Inc.|Synergistic bacterial compositions and methods of production and use thereof|

---

US9956282B2|2013-12-16|2018-05-01|Seres Therapeutics, Inc.|Bacterial compositions and methods of use thereof for treatment of immune system disorders|

---

US20150182736A1|2013-12-29|2015-07-02|Operating Room Innovations, Inc|Fecal matter transplant kit and method of using same|

---

EP3107553B1|2014-02-18|2021-12-01|Universitätsklinikum Jena|Methods and compositions for intestinal microenvironment transfer|

---

CA2941764A1|2014-03-07|2015-09-11|Dna Genotek Inc.|Composition and method for stabilizing nucleic acids in biological samples|

---

CN105624024B|2014-10-31|2018-01-19|南京法迈特科技发展有限公司|Microorganism separator in cavity content|

---

MA41020A|2014-11-25|2017-10-03|Evelo Biosciences Inc|PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME|

---

PT3193901T|2014-12-23|2018-06-29|4D Pharma Res Ltd|Pirin polypeptide and immune modulation|

---

CN104815389A|2015-03-27|2015-08-05|韩修建|Microbiological tumor therapeutic apparatus|

---

CN107709576A|2015-04-13|2018-02-16|优比欧迈公司|The diagnosis in microorganism group source and the method and system for the treatment of for nervous system health problem|

---

FR3035317B1|2015-04-24|2019-06-14|Maat Pharma|MICROORGANISM SAMPLING DEVICE, SAMPLING KIT COMPRISING SUCH A DEVICE AND SAMPLING METHOD USING SUCH A DEVICE|

---

FR3035328B1|2015-04-24|2019-08-23|Maat Pharma|PROCESS FOR PREPARING A MICROBIOTE FECAL SAMPLE|

---

JP6692897B2|2015-05-14|2020-05-13|クレストヴォ・ホールディングス・エルエルシー|Compositions for implanting stool flora, methods of preparing and using same, and devices for delivering same|

---

BR112017024777A2|2015-05-22|2018-08-07|Univ Arizona State|use of a pharmaceutical composition and a non-absorbable antibiotic for treating autistic spectrum disorder cross reference to related applications?|

---

US10905726B2|2015-06-09|2021-02-02|Rebiotix, Inc.|Microbiota restoration therapycompositions and methods of manufacture|

---

KR102066242B1|2015-06-09|2020-01-14|리바이오틱스, 인코퍼레이티드|Microbial Restoration TherapyCompositions and Methods of Preparation|

---

US10799539B2|2015-06-09|2020-10-13|Rebiotix, Inc.|Microbiota restoration therapycompositions and methods of manufacture|

---

US10828340B2|2015-06-09|2020-11-10|Rebiotix, Inc.|Microbiota restoration therapycompositions and methods of manufacture|

---

SI3307288T1|2015-06-15|2019-11-29|4D Pharma Res Ltd|Compositions comprising bacterial strains|

---

MA41010B1|2015-06-15|2020-01-31|4D Pharma Res Ltd|Compositions comprising bacterial strains|

---

AU2016278072B2|2015-06-15|2020-07-23|4D Pharma Research Limited|Compositions comprising bacterial strains|

---

MA41060B1|2015-06-15|2019-11-29|4D Pharma Res Ltd|Compositions comprising bacterial strains|

---

US11179421B2|2015-08-24|2021-11-23|Hygieacare, Inc.|Reducing uncomfortable side effects of abdominal distension in patients treated in hydrocolonic preparation units|

---

US10244980B2|2015-08-24|2019-04-02|Hygieacare, Inc|Large intestine contents' diagnosis and acoustic characterization|

---

US9775865B2|2015-08-24|2017-10-03|Hygieacare, Inc.|Large intestine contents' diagnosis and acoustic characterization|

---

WO2017075098A1|2015-10-26|2017-05-04|Crestovo Llc|Compositions and methods for fecal microbiota-related therapy|

---

GB201520497D0|2015-11-20|2016-01-06|4D Pharma Res Ltd|Compositions comprising bacterial strains|

---

CN112569262A|2015-11-20|2021-03-30|4D制药研究有限公司|Compositions comprising bacterial strains|

---

FR3045383B1|2015-12-18|2019-06-14|Maat Pharma|PROCESS FOR THE FREEZING OF A FECAL MICROBIOTE SAMPLE|

---

FR3045384B1|2015-12-18|2020-02-07|Institut National De La Recherche Agronomique|LYOPHILIZED COMPOSITION FOR THE PRESERVATION OF MICROBIOTE IN ITS ECOSYSTEM|

---

CN106144261B|2016-02-04|2019-02-22|中南大学湘雅三医院|It is a kind of for temporarily saving the free from extraneous odour anaerobism conserving case of fresh excreta|

---

EP3419638A4|2016-02-25|2019-10-02|Thomas Julius Borody|Compositions and methods of treatment of chronic infectious diseases|

---

JP6441536B2|2016-03-04|2018-12-19|フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ|Composition comprising a bacterial strain|

---

WO2017210428A1|2016-06-01|2017-12-07|Crestovo Llc|Compositions and methods for treating inflammatory bowel diseasesand other disorders|

---

US9999641B2|2016-06-14|2018-06-19|Vedanta Biosciences, Inc.|Treatment of clostridium difficile infection|

---

US20170360848A1|2016-06-15|2017-12-21|Arizona Board Of Regents On Behalf Of Arizona State University|Methods for treating autism spectrum disorder and associated symptoms|

---

US10849936B2|2016-07-01|2020-12-01|Regents Of The University Of Minnesota|Compositions and methods for C. difficile treatment|

---

US20180000872A1|2016-07-01|2018-01-04|Regents Of The University Of Minnesota|Compositions and methods for c. difficile treatment|

---

TW201821093A|2016-07-13|2018-06-16|英商４Ｄ製藥有限公司|Compositions comprising bacterial strains|

---

GB201612191D0|2016-07-13|2016-08-24|4D Pharma Plc|Compositions comprising bacterial strains|

---

EP3487513A1|2016-07-19|2019-05-29|Aobiome LLC|Ammonia oxidizing microorganisms for use and delivery to the gastrointestinal system|

---

US20180036352A1|2016-08-03|2018-02-08|Crestovo Holdings Llc|Methods for treating ulcerative colitis|

---

CN106399494B|2016-09-07|2019-08-06|泸州职业技术学院|The in vivo method of in situ detection analysis microbial interaction|

---

US10092601B2|2016-10-11|2018-10-09|Crestovo Holdings Llc|Compositions and methods for treating multiple sclerosis and related disorders|

---

WO2018071532A1|2016-10-11|2018-04-19|Crestovo Holdings Llc|Compositions and methods for treating chronic fatigue syndrome and related disorders|

---

WO2018071537A1|2016-10-11|2018-04-19|Crestovo Holdings Llc|Compositions and methods for treating multiple sclerosis and related disorders|

---

US11213549B2|2016-10-11|2022-01-04|Finch Therapeutics Holdings Llc|Compositions and method for treating primary sclerosing cholangitis and related disorders|

---

WO2018071534A1|2016-10-11|2018-04-19|Crestovo Holdings Llc|Compositions and methods for treating irritable bowel syndrome and related disorders|

---

AU2017350800A1|2016-10-31|2019-05-16|Kimberly-Clark Worldwide, Inc.|Method for archiving a microbiome|

---

US20200061127A1|2016-11-11|2020-02-27|Arizona Board Of Regents On Behalf Of Arizona State University|Methods and Compositions for Changing Metabolite Levels in a Subject|

---

GB201621123D0|2016-12-12|2017-01-25|4D Pharma Plc|Compositions comprising bacterial strains|

---

CA3049299A1|2017-01-19|2018-07-26|Pleonova Ab|Autologous fecal sample for use in the treatment of microbial dysbiosis|

---

CN110831606A|2017-04-05|2020-02-21|克雷斯顿沃控股公司|Compositions and methods for treating Parkinson's Diseaseand related disorders|

---

US11040073B2|2017-04-05|2021-06-22|Finch Therapeutics Holdings Llc|Compositions and methods for treating diverticulitis and related disorders|

---

CN107126445A|2017-04-20|2017-09-05|江南大学|Caprophyl is implanted in the application in terms for the treatment of Parkinson's|

---

JP2020520911A|2017-05-22|2020-07-16|フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ|Composition comprising a bacterial strain|

---

WO2018215782A1|2017-05-24|2018-11-29|4D Pharma Research Limited|Compositions comprising bacterial strain|

---

JP2020521760A|2017-05-26|2020-07-27|クレストヴォ・ホールディングス・エルエルシー|Lyophilized compositions containing fecal microbial-based therapeutic agents and methods of making and using same|

---

WO2018229188A1|2017-06-14|2018-12-20|4D Pharma Research Limited|Compositions comprising bacterial strains|

---

RS60910B1|2017-06-14|2020-11-30|4D Pharma Res Ltd|Compositions comprising a bacterial strain of the genus megasphaera and uses thereof|

---

RU2659417C1|2017-06-22|2018-07-02|Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии"|Device for preparation of donor fecal material for transplantation|

---

US20210121503A1|2017-10-12|2021-04-29|Crestovo Holdings Llc|Fecal microbiota transplantation for treating ulcerative colitis|

---

CN108578840A|2018-05-03|2018-09-28|苏州高新区建金建智能科技有限公司|A kind of medical optical fiber injection needle with laser illumination function|

---

CN108478906A|2018-05-03|2018-09-04|苏州高新区建金建智能科技有限公司|A kind of medical Multi needle optical fiber injection device with activation probiotics function|

---

CN108578841A|2018-05-03|2018-09-28|苏州高新区建金建智能科技有限公司|A kind of medical optical fiber injection needle with medicine liquid heating function|

---

US11166990B2|2018-07-13|2021-11-09|Finch Therapeutics Holdings Llc|Methods and compositions for treating ulcerative colitis|

---

CN108567799A|2018-08-01|2018-09-25|中国人民解放军总医院|A kind of full caprophyl complex capsule and its preparation method and application|

---

US20220000940A1|2018-09-27|2022-01-06|Finch Therapeutics Holdings Llc|Compositions and methods for treating epilepsy and related disorders|

---

JPWO2020196724A1|2019-03-27|2021-04-08|株式会社晩聲社|Bacterial flora transplanting composition, its manufacturing method, transplanting equipment and transplanting method|

---

WO2021050965A1|2019-09-13|2021-03-18|Crestovo Holdings Llc|Compositions and methods for treating autism spectrum disorder|

---

WO2021077107A1|2019-10-18|2021-04-22|Crestovo Holdings Llc|Compositions and methods for delivering a bacterial metabolite to a subject|

---

WO2021097288A1|2019-11-15|2021-05-20|Finch Therapeutics Holdings Llc|Compositions and methods for treating neurodegenerative diseases|

---

WO2021142358A1|2020-01-10|2021-07-15|Finch Therapeutics Holdings Llc|Compositions and methods for treating hepatic encephalopathy |

---

WO2021142347A1|2020-01-10|2021-07-15|Finch Therapeutics Holdings Llc|Compositions and methods for non-alcoholic steatohepatitis |

---

WO2021142353A1|2020-01-10|2021-07-15|Finch Therapeutics Holdings Llc|Compositions and methods for treating hepatitis band hepatitis d |

---

WO2021195636A1|2020-03-27|2021-09-30|Cornell University|Microbiome-based therapeutics|

---

WO2021202806A1|2020-03-31|2021-10-07|Finch Therapeutics Holdings Llc|Compositions comprising non-viable fecal microbiota and methods of use thereof|

---

RU2745125C1|2020-07-15|2021-03-22|Общество с ограниченной ответственностью «Байкальский центр биомедицинских исследований» |Device and the method for preparation in anaerobic conditions of donor fecal microbiota for transplantation|

---

RU2761047C1|2021-03-10|2021-12-02|Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии"|Device for preparing donor fecal material for transplantation|

法律状态:
2017-10-24| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-05-15| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2019-05-14| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2019-11-26| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-02-04| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/08/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

AU2010903474A|AU2010903474A0|2010-08-04|Faecal Transplantation Methodology|

---

US201161450099P| true| 2011-03-07|2011-03-07|

---

US201161451087P| true| 2011-03-09|2011-03-09|

---

US201161483487P| true| 2011-05-06|2011-05-06|

---

US201161494363P| true| 2011-06-07|2011-06-07|

---

PCT/AU2011/000987|WO2012016287A2|2010-08-04|2011-08-04|Compositions for fecal floral transplantation and methods for making and using them and devices for deuvering them|

---